Compare versions
--- version:Bill Text+++ version:(document, no version)@@ -1,14222 +1,291 @@-LEGISLATURE+ST+A+TEMENTOF-THE-STATE-OF-IDAHO-Sixty-eighth-Legislature-Second-Regular-Session---2026-IN-THE-HOUSE-OF-REPRESENTATIVES-HOUSE-BILL-NO.-777-BY-HEALTH-AND-WELFARE-COMMITTEE-AN-ACT-1-RELATING-TO-UNIFORM-CONTROLLED-SUBSTANCES;-AMENDING-SECTION-37---2705,-IDAHO-2-CODE,-TO-REVISE-PROVISIONS-REGARDING-SCHEDULE-I-CONTROLLED-SUBSTANCES-3-AND-TO-MAKE-TECHNICAL-CORRECTIONS;-AMENDING-SECTION-37---2707,-IDAHO-4-CODE,-TO-REVISE-PROVISIONS-REGARDING-SCHEDULE+PURPOSE+RS33450+/+H0777+This+legislation+updates+the+Idaho+Controlled+Substances+Act+to+align+with+recent+federal+scheduling+actions+taken+by+the+U.S.+Drug+Enforcement+Administration+and+corrects+spelling,+numbering,+and+other+drafting+errors+that+have+been+perpetuated+through+prior+versions+of+the+Act.+It+updates+ArticleII-CONTROLLED-SUBSTANCES-5-AND-TO-MAKE-TECHNICAL-CORRECTIONS;-AMENDING-SECTION-37---2709,-IDAHO-6-CODE,-TO-REVISE-PROVISIONS-REGARDING-SCHEDULE-III-CONTROLLED-SUB---7-STANCES-AND-TO-MAKE-TECHNICAL-CORRECTIONS;-AMENDING-SECTION-37---2711,-8-IDAHO-CODE,-TO-REVISE-PROVISIONS-REGARDING-SCHEDULE-IV-CONTROLLED-SUB---9-STANCES-AND-TO-MAKE-TECHNICAL-CORRECTIONS;-AMENDING-SECTION-37---2713,-10-IDAHO-CODE,-TO-REVISE-PROVISIONS-REGARDING-SCHEDULE-V-CONTROLLED-SUB---1-1-STANCES;-AMENDING-SECTION-37---2716,-IDAHO-CODE,-TO-REVISE-PROVISIONS-12-REGARDING-REGISTRATION-REQUIREMENTS;-AMENDING-SECTION-37---2717,-IDAHO-13-CODE,-TO-REVISE-A-PROVISION-REGARDING-REGISTRATION;-AMENDING-SEC---14-TION-37---2718,-IDAHO-CODE,-TO-REVISE-PROVISIONS-REGARDING-DISCIPLINE;-15-AMENDING-SECTION-37---2719,-IDAHO-CODE,-TO-REVISE-PROVISIONS-REGARD---16-ING-ORDERS-TO-SHOW-CAUSE;-AMENDING-SECTION-37---2720,-IDAHO-CODE,-TO-17-REVISE-A-PROVISION-REGARDING-RECORDS,-DRUG-STORAGE,-AND-INVENTORY;-18-AMENDING-SECTION-37---2722,-IDAHO-CODE,-TO-REVISE-PROVISIONS-REGARDING-19-ISSUING,-DISTRIBUTING,-AND-DISPENSING-OF-CONTROLLED-SUBSTANCES-AND-TO-20-MAKE-TECHNICAL-CORRECTIONS;-AMENDING-SECTION-37---2726,-IDAHO-CODE,-TO-21-REVISE-PROVISIONS-REGARDING-THE-CONTROLLED-SUBSTANCES-PRESCRIPTIONS-22-DATABASE;-AMENDING-SECTION-37---2731,-IDAHO-CODE,-TO-REVISE-A-PROVISION-23-REGARDING-INFORMATION-REQUIRED-ON-LABELS;-AND-DECLARING-AN-EMERGENCY-24-AND-PROVIDING-AN-EFFECTIVE-DATE.-25-Be-It-Enacted-by-the-Legislature-of-the-State-of-Idaho:-26-SECTION-1.-That-Section-37---2705,-Idaho-Code,-be,-and-the-same-is-hereby-27-amended-to-read-as-follows:-28-37---2705.-SCHEDULE-I.-(a)-The+by+adding+illicit+substances+with+no+approved+medical+use+to+Schedule+I,+incorporating+newly+scheduled+and+other+federallycontrolledsubstances-listed-in-this-sec---29-tion-are-included-in-schedule-I.-30-(b)-Any-of-the-following-opiates,+into+Schedules+II,+III,+and+IV+,+and+removing+outdated+or+duplicative+entries,including-their-isomers,-esters,-31-ethers,-salts,-and-salts-of-isomers,-esters,-and-ethers,-unless-specifically-32-excepted,-whenever-the-existence-of-these-isomers,-esters,-ethers-and-salts-33-is-possible-within-the-specific+unnecessary+and+cumbersomechemical-designation:-34-(1)-Acetyl---alpha---methylfentanyl-(N---[1---(1---methyl---2---phenethyl)---4---pip---35-eridinyl]---N---phenylacetamide)-;-36-(2)-Acetylmethadol;-37-(3)-Acetyl-fentanyl-(N---(1---phenethylpiperidin---4---yl)---N---phenylac---38-etamide)-;-39-(4)-Acryl-fentanyl-(N---(1---phenethylpiperidin---4---yl)---N---phenylacry---40-lamide)-;-41-(5)-Allylprodine;-42--2-(6)-Alphacetylmethadol-(except-levo---alphacetylmethadol-also-known-as-1-levo---alpha---acetylmethadol,-levomethadyl-acetate-or-LAAM);-2-(7)-Alphameprodine;-3-(8)-Alphamethadol;-4-(9)-Alpha'---methyl-butyryl-fentanyl-(2---methyl---N---(1---phenethylpiperidi---5-n---4---yl)---N---phenylbutanamide)-;-6-(10)-Alpha---methylfentanyl;-7-(11)-Alpha---methylthiofentanyl-(N---[1---methyl---2---(2---thienyl)ethyl---4---8-piperidinyl]---N---phenylpropanamide)-;-9-(12)-Benzethidine;-10-(13)-Betacetylmethadol;-1-1-(14)-Beta---hydroxyfentanyl-(N---[1---(2---hydroxy---2---phenethyl)---4---piperid---12-inyl]---N---phenylpropanamide)-;-13-(15)-Beta---hydroxythiofentanyl;-14-(16)-Beta---hydroxy---3---methylfentanyl-(N---(1---(2---hydroxy---2---phenethyl)---3---15-methyl---4---piperidinyl)---N---phenylpropanamide)-;-16-(17)-Betameprodine;-17-(18)-Betamethadol;-18-(19)-Beta---methyl-fentanyl;-19-(20)-Beta---methylacetyl-fentanyl;-20-(20)-(21)-Beta'---phenyl-fentanyl;-21-(21)-(22)-Betaprodine;-22-(22)-(23)-Brorphine-(1---(1---(1---(4---Bromophenyl)ethyl)piperidin---4---yl)---23-1,3---dihydro---2H---benzo[D]imidazol---2---one)-;-24-(23)-(24)-Butonitazene-(2---(2---(4---butoxybenzyl)---5---nitro---1hbenzimida---25-zol---1---yl)---N,N---diethylethan---1---amine)-;-26-(24)-(25)-Clonitazene;-27-(25)-(26)-Crotonyl-fentanyl-((E)---N---(1---phenethylpiperidin---4---yl)---N---28-phenylbut---2---enamide)-;-29-(26)-(27)-Cyclopentyl-fentanyl-(N---(1---phenethylpiperidin---4---yl)---N---30-phenylcyclopentanecarboxamide)-;-31-(27)-(28)-Cyclopropyl-fentanyl-(N---(1---phenethylpiperidin---4---yl)---N---32-phenylcyclopropanecarboxamide)-;-33-(28)-(29)-Dextromoramide;-34-(29)-(30)-Diampromide;-35-(30)-(31)-Diethylthiambutene;-36-(31)-(32)-Difenoxin;-37-(32)-(33)-Dimenoxadol;-38-(33)-(34)-Dimepheptanol;-39-(34)-(35)-2',5'---Dimethoxyfentanyl-(N---(1---(2,5---dimethoxyphenethyl)pip---40-eridin---4---yl)---N---phenylpropionamide)-;-41-(35)-(36)-Dimethylthiambutene;-42-(36)-(37)-Dioxaphetyl-butyrate;-43-(37)-(38)-Dipipanone;-44-(38)-(39)-Ethylmethylthiambutene;-45-(39)-(40)-Etodesnitazene-;-(-Etazene-)-(2---(2---(4---ethoxybenzyl)---1hbenzim---46-idazol---1---yl)---N,N---diethylethan---1---amine)-;-47-(40)-(41)-Etonitazene;-48-(41)-(42)-Etoxeridine;-49--3-(42)-(43)-Fentanyl---related-substances.-"Fentanyl---related-substances"-1-means-any-substance-not-otherwise-listed-and-for-which-no-exemption-or-2-approval-is-in-effect-under-section-505-of-the-federal-food,-drug,-and-3-cosmetic-act,-21-U.S.C.-355,-and-that-is-structurally-related-to-fen---4-tanyl-by-one-(1)-or-more-of-the-following-modifications:-5-i.-Replacement-of-the-phenyl-portion-of-the-phenethyl-group-by-any-6-monocycle,-whether-or-not-further-substituted-in-or-on-the-monocy---7-cle;-8-ii.-Substitution-in-or-on-the-phenethyl-group-with-alkyl,-alkenyl,-9-alkoxyl,-hydroxyl,-halo,-haloalkyl,-amino,-or-nitro-groups;-10-iii.-Substitution-in-or-on-the-piperidine-ring-with-alkyl,-1-1-alkenyl,-alkoxyl,-ester,-ether,-hydroxyl,-halo,-haloalkyl,-amino,-12-or-nitro-groups;-13-iv.-Replacement-Substitution-in-or-on-the-aniline-ring-or-replace---14-ment-of-the-aniline-ring-with-any-aromatic-monocycle,-whether-or-15-not-further-substituted-in-or-on-the-aromatic-monocycle;-and/or-16-v.-Replacement-of-the-N---propionyl-group-by-another-acyl-group;-17-(43)-(44)-Fentanyl-carabamate;-18-(44)-(45)-Flunitazene-(N,N---diethyl---2---(2---(4---fluorobenzyl)---5---nitro---1h---19-benzimidazol---1---yl)ethan---1---amine)-;-20-(45)-(46)-4---Fluoroisobutyryl-fentanyl-(N---(4---fluorophenyl)---N---(1---21-phenethylpiperidin---4---yl)isobutyramide)-;-22-(46)-(47)-2'---fluoro-ortho---fluorofentanyl;-23-(47)-(48)-Furanyl-fentanyl-(N---(1---phenethylpiperidin---4---yl)---N---phenyl---24-furan---2---carboxamide)-;-25-(48)-(49)-3---Furanyl-fentanyl-(N---(1---phenethylpiperidin---4---yl)---N---26-phenylfuran---3---carboxamide)-;-27-(49)-(50)-Furethidine;-28-(50)-(51)-Hydroxypethidine;-29-(51)-(52)-Isobutyryl-fentanyl-(N---(1---phenethylpiperidin---4---yl)---N---30-phenylisobutyramide)-;-31-(52)-(53)-Isovalery-fentanyl-(3---methyl---N---(1---phenethylpiperidin---4---32-yl)---N---phenylbutanimide)-;-33-(53)-(54)-Isotonitazene-(N,N---diethyl---2---(2---(4isopropoxybenzyl)---5---ni---34-tro---1h---benzimidazol---1---yl)ethan---1---amine)-;-35-(54)-(55)-Ketobemidone;-36-(55)-(56)-Levomoramide;-37-(56)-(57)-Levophenacylmorphan;-38-(57)-(58)-Meta---fluorofentanyl-(N---(3---fluorophenyl)---N---(1---39-phenethylpiperidin---4---yl)isobutyramide)-;-40-(59)-Meta---fluorofuranyl-fentanyl;-41-(58)-(60)-Meta---fluoroisobutyryl-fentanyl-(N---(3---fluorophenyl)---N---(1---42-phenethylpiperidin---4---yl)isobutyramide)-;-43-(59)-(61)-Methoxyacetyl-fentanyl-(2---methoxy---N---(1---phenethylpiperidin---44-4---yl)---N---phenylacetamide)-;-45-(60)-(62)-2---Methyl-AP---237-(1---(2---methyl---4---(3---phenylprop---2---en---1---46-yl)piperazin---1---yl)butan---1---one)-;-47-(61)-(63)-4'---methyl-acetyl-fentanyl;-48-(62)-(64)-3---Methylfentanyl;-49--4-(63)-(65)-3---methylthiofentanyl-(N---[(3---methyl---1---(2---thienyl)ethyl---4---1-piperidinyl]---N---phenylpropanamide)-(and-optical-and-geometric-isomers-2-of-3---methylthiofentanyl)-;-3-(64)-(66)-Metodesnitazene-(N,N---diethyl---2---(2---(4---methoxybenzyl)---1h---4-benzimidazol---1---yl)ethan---1---amine)-;-5-(65)-(67)-Metonitazene-(N,N---diethyl---2---(2---(4---methoxybenzyl)---5---ni---6-tro---1hbenzimidazol---1---yl)ethan---1---amine)-;-7-(66)-(68)-Morpheridine;-8-(67)-(69)-MPPP-(1---methyl---4---phenyl---4---propionoxypiperidine);-9-(68)-(70)-MT---45-(1---cyclohexyl---4---(1,2---diphenylethyl)piperazine);-10-(69)-(71)-N---(4---chlorophenyl)---N---(1---phenethylpiperdin---4---yl)Isobutyra---1-1-mide-(p-P-ara---chloroisobutyrl-fentanyl-)-;-12-(70)-(72)-Noracymethadol;-13-(71)-(73)-Norlevorphanol;-14-(72)-(74)-Normethadone;-15-(73)-(75)-Norpipanone;-16-(76)-N---desethyl-isotonitazene;-17-(77)-N---piperidinyl-etonitazene;-18-(74)-(78)-N---pyrrolidino-etonitazene-(2---(4---ethoxybenzyl)---5---ni---19-tro---1---(2---(pyrrolidin---1---yl)ethyl)1hbenzimidazole)-;-20-(75)-(79)-Ocfentanil-(N---(2---fluorophenyl)---2---methoxy---N---(1---phenethyl---21-piperidin---4---yl)acetamide)-;-22-(80)-Ortho---chlorofentanyl;-23-(76)-(81)-Ortho---fluoroacryl-fentanyl;-24-(77)-(82)-Ortho---fluorobutyrl-fentanyl;-25-(78)-(83)-Ortho---fluorofentanyl;-26-(79)-(84)-Ortho---fluorofuranyl-fentanyl-(N---(2---fluorophenyl)---N---(1---27-phenethylpiperidin---4---yl)furan---2---carboxamide)-;-28-(80)-(85)-Ortho---fluoroisobutyryl-fentanyl;-29-(81)-(86)-Ortho---methyl-acetylfentanyl;-30-(87)-Ortho---methylcyclopropylfentanyl;-31-(82)-(88)-Ortho---methyl-methoxyacetyl-fentanyl;-32-(89)-Para---chlorofentanyl;-33-(83)-(90)-Para---chloroisobutyryl-fentanyl-(N---(4---chlorophenyl)---N---(1---34-phenethylpiperidin---4---yl)-isobutyramide)-;-35-(84)-(91)-Para---fluorobutyryl-fentanyl-(N---(4---fluorophenyl)---N---(1---36-phenethylpiperidin---4---yl)-butyramide)-;-37-(85)-(92)-Para---fluorofentanyl-(N---(4---fluorophenyl)---N---[1---(2---phen---38-ethyl)---4---piperidinyl]-propanamide)-;-39-(86)-(93)-Para---fluoro-furanyl-fentanyl;-40-(94)-Para---fluoro-valeryl-fentanyl;-41-(87)-(95)-Para---methoxybutyryl-fentanyl-(N---(4---methoxyphenyl)---N---(1---42-phenethylpiperidin---4---yl)-butyramide)-;-43-(88)-(96)-Para---methoxyfuranyl-fentanyl-(N---(4---methoxyphenyl)---N---(1---44-phenethylpiperidin---4---yl)furan---2---carboxamide)-;-45-(89)-(97)-Para---methylcyclopropyl-fentanyl-(N---(4---methylphenyl)---N---(1---46-phenylpiperidin---4---yl)cyclopropanecarboxamide)-;-47-(90)-(98)-Para---methylfentanyl;-48-(91)-(99)-PEPAP-(1---(---2---phenethyl)---4---phenyl---4---acetoxypiperidine);-49-(92)-(100)-Phenadoxone;-50--5-(93)-(101)-Phenampromide;-1-(94)-(102)-Phenomorphan;-2-(95)-(103)-Phenoperidine;-3-(96)-(104)-Phenyl-fentanyl;-4-(97)-(105)-Piritramide;-5-(98)-(106)-Proheptazine;-6-(99)-(107)-Properidine;-7-(100)-(108)-Propiram;-8-(101)-(109)-Protonitazene-(N,N---diethyl---2---(5---nitro---2---(4---propoxyben---9-zyl)---1h---benzimidazol---1---yl)ethan---1---amine)-;-10-(102)-(110)-Racemoramide;-1-1-(103)-(111)-Tetrahydrofuranyl-fentanyl-(N---(1---phenethylpiperi---12-dine---4---yl)---N---phenyltetrahydrofuran---2---carboxamide)-;-13-(112)-Tetrahydrothiofuranyl-fentanyl;-14-(104)-(113)-Thiofentanyl-(N---phenyl---N---[1---(2---thienyl)ethyl---4---piper---15-idinyl]---propanamide)-;-16-(105)-(114)-Tilidine;-17-(106)-(115)-Trimeperidine;-18-(107)-(116)-u---47700-(3,4---Dichloro---N---[2---(dimethylamino)cyclohexyl]---N---19-methylbenzamide);-20-(108)-(117)-Valeryl-fentanyl-(N---(1---phenethylpiperidin---4---yl)---N---21-phenylpentanamide)-;-22-(109)-(118)-Zipeprol-(1---methoxy---3---[4---(2---methoxy---2---phenylethyl)piper---23-azin---1---yl]---1---phenylpropan---2---ol)-.-24-(c)-Any-of-the-following-opium-derivatives,-their-salts,-isomers-and-25-salts-of-isomers,-unless-specifically-excepted,-whenever-the-existence-of-26-these-salts,-isomers-and-salts-of-isomers-is-possible-within-the-specific-27-chemical-designation:-28-(1)-Acetorphine;-29-(2)-Acetyldihydrocodeine;-30-(3)-Benzylmorphine;-31-(4)-Codeine-methylbromide;-32-(5)-Codeine---N---Oxide;-33-(6)-Cyprenorphine;-34-(7)-Desomorphine;-35-(8)-Dihydromorphine;-36-(9)-Drotebanol;-37-(10)-Etorphine-(except-hydrochloride-salt);-38-(11)-Heroin;-39-(12)-Hydromorphinol;-40-(13)-Methyldesorphine;-41-(14)-Methyldihydromorphine;-42-(15)-Morphine-methylbromide;-43-(16)-Morphine-methylsulfonate;-44-(17)-Morphine---N---Oxide;-45-(18)-Myrophine;-46-(19)-Nicocodeine;-47-(20)-Nicomorphine;-48-(21)-Normorphine;-49-(22)-Pholcodine;-50--6-(23)-Thebacon.-1-(d)-Hallucinogenic-substances.-Any-material,-compound,-mixture-or-2-preparation-that-contains-any-quantity-of-the-following-hallucinogenic-3-substances,-their-salts,-isomers-and-salts-of-isomers,-unless-specifically-4-excepted,-whenever-the-existence-of-these-salts,-isomers,-and-salts-of-iso---5-mers-is-possible-within-the-specific-chemical-designation-(for-purposes-of-6-this-subsection-only,-the-term-"isomer"-includes-the-optical,-position-and-7-geometric-isomers):-8-(1)-Dimethoxyphenethylamine,-or-any-compound-not-specifically-9-excepted-or-listed-in-another-schedule-that-can-be-formed-from-10-dimethoxyphenethylamine-by-replacement-of-one-(1)-or-more-hydrogen-1-1-atoms-with-another-atom(s),-functional-group(s)-or-substructure(s)-12-including,-but-not-limited-to,-compounds-such-as-DOB,-DOC,-2C---B,-13-25B---NBOMe;-14-(2)-Methoxyamphetamine-or-any-compound-not-specifically-excepted-or-15-listed-in-another-schedule-that-can-be-formed-from-methoxyamphetamine-16-by-replacement-of-one-(1)-or-more-hydrogen-atoms-with-another-atom(s),-17-functional-group(s)-or-substructure(s)-including,-but-not-limited-to,-18-compounds-such-as-PMA-and-DOM;-19-(3)-5---methoxy---3,4---methylenedioxy---amphetamine;-20-(4)-5---methoxy---N,N---diisopropyltryptamine-(5---MeO---DIPT)-;-21-(5)-Amphetamine-or-methamphetamine-with-a-halogen-substitution-on-the-22-benzyl-ring,-including-compounds-such-as-fluorinated-amphetamine-and-23-fluorinated-methamphetamine;-24-(6)-3,4---methylenedioxy-amphetamine-(MDA)-;-25-(7)-3,4---methylenedioxymethamphetamine-(MDMA);-26-(8)-3,4---methylenedioxy---N---ethylamphetamine-(-also-known-as-N---et---27-hyl---alpha---methyl---3,4-(methylenedioxy)-phenethylamine,-and-N---et---28-hyl-MDA,-MDE,-MDEA);-29-(9)-N---hydroxy---3,4---methylenedioxyamphetamine-(-also-known-as-N---hyd---30-roxy---alpha---methyl---3,4(methylenedioxy)-phenethylamine,-and-N---hyd---31-roxy-MDA);-32-(10)-3,4,5---trimethoxy-amphetamine;-33-(11)-5---methoxy---N,N---dimethyltryptamine-(-also-known-as-5---methoxy---3---2[2---34-(dimethylamino)ethyl]indole-and-5---MeO---DMT);-35-(12)-Alpha---ethyltryptamine-(-some-other-names:-etryptamine,-3---(2---am---36-inobutyl)-indole-AET-);-37-(13)-Alpha---methyltryptamine-(AMT)-;-38-(14)-Bufotenine;-39-(15)-Diethyltryptamine-(DET);-40-(16)-Dimethyltryptamine-(DMT);-41-(17)-Ibogaine;-42-(18)-Lysergic-acid-diethylamide-(LSD)-;-43-(19)-Marihuana-(marijuana)-;-44-(20)-Mescaline;-45-(21)-Methoxetamine;-46-(22)-Parahexyl;-47-(23)-Peyote;-48-(24)-N---ethyl---3---piperidyl-benzilate;-49-(25)-N---methyl---3---piperidyl-benzilate;-50--7-(26)-Para---methoxymethamphetamine-(PMMA)-,-1---(4---methoxyphenyl)---N---1-methylpropan---2---amine-;-2-(27)-Psilocybin;-3-(28)-Psilocyn;-4-(29)-Tetrahydrocannabinols-or-synthetic-equivalents-of-the-substances-5-contained-in-the-plant,-or-in-the-resinous-extractives-of-Cannabis,-sp.-6-and/or-synthetic-substances,-derivatives,-and-their-isomers-with-simi---7-lar-chemical-structure-such-as-the-following:-8-i.-Tetrahydrocannabinols,-except-for-the-permitted-amount-of-9-tetrahydrocannabinol-found-in-industrial-hemp,-or-nabiximols-in-a-10-drug-product-approved-by-the-United-States-food-and-drug-adminis---1-1-tration:-12-a.-∆-1-cis-or-trans-tetrahydrocannabinol,-and-their-opti---13-cal-isomers,-excluding-dronabinol-in-sesame-oil-and-encapsu---14-lated-in-either-a-soft-gelatin-capsule-or-in-an-oral-solution-15-in-a-drug-product-approved-by-the-U.S.-Food-and-Drug-Adminis---16-tration.-17-b.-∆-6-cis-or-trans-tetrahydrocannabinol,-and-their-optical-18-isomers.-19-c.-∆-3-,-4-cis-or-trans-tetrahydrocannabinol,-and-its-optical-20-isomers.-(Since-nomenclature-of-these-substances-is-not-in---21-ternationally-standardized,-compounds-of-these-structures,-22-regardless-of-numerical-designation-of-atomic-positions-are-23-covered.)-24-d.-[(6aR,10aR)---9---(hydroxymethyl)---6,6---dimethyl---3---(2methy---25-loctan---2---yl)---6a,7,10,10a---tetrahydrobenzo[c]chromen---26-1---o1)],-also-known-as-6aR---trans---3---(1,1---dimethylhep---27-tyl)---6a,7,10,10a---tetrahydro---1---hydroxy---6,6---dimethyl---6H---28-dibenzo[b,d]pyran---9---methanol-(HU---210)-and-its-geometric-29-isomers-(HU211-or-dexanabinol).-30-ii.-The-following-synthetic-drugs:-31-a.-Any-compound-structurally-derived-from-(1H---indole---3---32-yl)(cycloalkyl,-cycloalkenyl,-aryl)methanone,-or-(1H---in---33-dole---3---yl)(cycloalkyl,-cycloalkenyl,-aryl)methane,-or-34-(1H---indole---3---yl)(cycloalkyl,-cycloalkenyl,-aryl-)-,-methyl-35-or-dimethyl-butanoate,-amino---methyl-(or-dimethyl)---1---oxobu---36-tan---2---yl)-carboxamide-by-substitution-at-the-nitrogen-atoms-37-of-the-indole-ring-or-carboxamide-to-any-extent,-whether-or-38-not-further-substituted-in-or-on-the-indole-ring-to-any-ex---39-tent,-whether-or-not-substituted-to-any-extent-in-or-on-the-40-cycloalkyl,-cycloalkenyl,-aryl-ring(s)-(substitution-in-the-41-ring-may-include,-but-is-not-limited-to,-heteroatoms-such-as-42-nitrogen,-sulfur-and-oxygen).-43-b.-N---(1---amino---3---methyl---1---oxobutan---2---yl)---1---(5---fluo---44-ropentyl)---1-H---indazole---3---carboxamide-(5F---AB---PINACA).-45-c.-1---(1.3---benzodioxol---5---yl)---2---(ethylamino)---pentan---1---one-46-(-N---ethylpentylone-,-(-ephylone).-47-d.-1---(4---cyanobutyl)---N---(2---phenylpropan---2---yl)---1-H---inda---48-zole---3---carboxamide-(4---cn---cumyl---BUTINACA).-49--8-e.-5---pentyl---2---(2---phenylpropan---2---yl)pyrido[4,3---b]indol---1---1-one-(Cumyl-PeGACLONE-Pegaclone-).-2-f.-Ethyl-2---(1---(5---fluoropentyl)---1H---indazole---3carboxam---3-ido)---3,3---dimethylbutanoate-*-(5F---EDMB---PINACA).-4-g.-Ethyl-2---(1---(5---fluoropentyl)---1H---indole---3---carboxamido)---5-3,3---dimethylbutanoate-(5F---EDMB---PICA).-6-h.-(1---(4---fluorobenzyl)---1H---indol---3---yl)(2,2,3,3tetram---7-ethylcyclopropyl)methanone-(FUB---144).-8-i.-1---(5---fluoropentyl)---N---(2---phenylpropan---2---yl)---1H---inda---9-zole---3---carboxamide-(5f---cumyl---pinaca;-SGT---25).-10-j.-(1---(5---fluoropentyl)---N---(2---phenylpropan---2---yl)---1-1-1-H---pyrrolo[2.3---B]pyridine---3---carboxamide(5fcumyl---P7AICA).-12-k.-FUB---AMB,-MMB---FUBINACA-(Methyl-2---(1---(4---fluoroben---13-zyl)---1H---indazole---3---carboxamido)---3---methylbutanoate.-14-l.-MMB---FUBICA-(Methyl-2---(1---(4---Fluorobenzyl)---1H---Indole---3---15-carboxamido)---3---methyl-butanoate).-16-m.-Methyl-3,3---dimethyl---2---((1---(pent---4---en---1---yl)---1H---in---17-dazol-e---3---yl)formamido-carboxamido-)butanoate-(MDMB---4EN---18-PINACA).-19-n.-Methyl-2---(1---(cyclohexylmethyl)---1H---indole---3---carboxam---20-ido)---3---methylbutanoate-(MMB---CHMICA,-AMB---CHMICA).-21-o.-Methyl-2---(1---(cyclohexylmethyl)---1H---indole---3---carboxam---22-ido)---3,3---dimethylbutanoate-(MDMB---CHMICA-,-MMB---CHMINACA-).-23-p.-Methyl-2---(1---(4---fluorobenzyl)---1H---indazole---3---carboxam---24-ido---3,3---dimethylbutanoate-(MDMB---FUBINACA).-25-q.-Methyl-2---[[1---(4---Fluorobutyl)Indole---3---Carbonyl]Amino]---26-3,3---Dimethyl---Butanoate-(4F---MDMB---BUTICA-,-4F---MDMB---BICA-).-27-r.-Methyl-2---(1---(5---fluoropentyl)---1H---indole---3---carboxam---28-ido)---3,3---dimethylbutanoate-(5F---MDMB---PICA-,-5F---MDMB---2201-).-29-s.-Methyl-2---(1---(5---fluoropentyl)---1H---indazole---3---carboxam---30-ido)---3,3---dimethylbutanoate-(5F---ADB,-5F---MDMB---PINACA).-31-t.-Methyl-2---(1---(5---fluoropentyl)---1H---indazole---3---carboxam---32-ido)---3---methylbutanoate-(5F---AMB).-33-u.-N---(1---Amino---3,3---dimethyl---1---oxobutan---2---yl)---1---butyl---1H---34-Indazole---3---carboxamide-(ADB---BUTINACA).-35-v.-N---(1---amino---3,3---dimethyl---1---oxobutan---2---yl)---1---(4---fluo---36-robenzyl)---1H---indazole---3---carboxamide-(ADB---FUBINACA).-37-w.-N---(1---Amino---3,3---dimethyl---1---oxobutan---2---yl)---1---(pent---4---38-en---1---yl)---1H---indazole---3---carboxamide-(ADB---4EN---PINACA).-39-x.-N---(adamantan---1---yl)---1---(4---fluorobenzyl)---1H---indazole---3---40-carboxamide-(FUB---AKB48;-FUB---APINACA).-41-y.-N---(adamantan---1---yl)---1---(5---fluoropentyl)---1H---indazole---3---42-carboxamide-(5F---APINACA,-5F---AKB48).-43-z.-N---(1---amino---3---methyl---1---oxobutan---2---yl)1---(Cyclohexyl---44-methyl)---1H---indazole---3---carboxamide-(AB---CHMINACA).-45-aa.-Naphthalen---1---yl-1---(5---fluoropentyl)---1H---indole---3---car---46-boxylate-(NM2201;-CBL2201).-47-bb.-Any-compound-structurally-derived-from-3---(1---naph---48-thoyl)pyrrole-by-substitution-at-the-nitrogen-atom-of-the-49-pyrrole-ring-to-any-extent,-whether-or-not-further-sub---50--9-stituted-in-the-pyrrole-ring-to-any-extent,-whether-or-not-1-substituted-in-the-naphthyl-ring-to-any-extent.-2-cc.-Any-compound-structurally-derived-from-1---(1---naphthyl---3-methyl)indene-by-substitution-at-the-3---position-of-the-in---4-dene-ring-to-any-extent,-whether-or-not-further-substituted-5-in-the-indene-ring-to-any-extent,-whether-or-not-substituted-6-in-the-naphthyl-ring-to-any-extent.-7-dd.-Any-compound-structurally-derived-from-3---pheny---8-lacetylindole-by-substitution-at-the-nitrogen-atom-of-the-9-indole-ring-to-any-extent,-whether-or-not-further-substi---10-tuted-in-the-indole-ring-to-any-extent,-whether-or-not-sub---1-1-stituted-in-the-phenyl-ring-to-any-extent.-12-ee.-Any-compound-structurally-derived-from-2---(3---hydroxy---13-cyclohexyl)phenol-by-substitution-at-the-5---position-of-the-14-phenolic-ring-to-any-extent,-whether-or-not-substituted-in-15-the-cyclohexyl-ring-to-any-extent.-16-ff.-Any-compound-structurally-derived-from-3---(benzoyl)in---17-dole-structure-with-substitution-at-the-nitrogen-atom-of-18-the-indole-ring-to-any-extent,-whether-or-not-further-sub---19-stituted-in-the-indole-ring-to-any-extent-and-whether-or-not-20-substituted-in-the-phenyl-ring-to-any-extent.-21-gg.-[2,3---dihydro---5---methyl---3---(4---morpholinyl---22-methyl)pyrrolo[1,2,3---de]---1,4---benzoxazin---6---yl]---1---23-napthalenylmethanone-(WIN---55,212---2).-24-hh.-3---dimethylheptyl---11---hydroxyhexahydrocannabinol-(HU---25-243).-26-ii.-[(6S,-6aR,-9R,-10aR)---9---hydroxy---6---methyl---3---[(2R)---27-5---phenylpentan---2---yl]oxy---5,6,6a,7,8,9,10,10a---octahy---28-drophenanthridin---1---yl]acetate-(CP-50,5561).-29-(30)-Ethylamine-analog-of-phencyclidine:-N---ethyl---1---phenylcy---30-clohexylamine-(1---phenylcyclohexyl)-ethylamine;-N---(1---phenylcy---31-clohexyl)-ethylamine,-cyclohexamine,-PCE;-32-(31)-Pyrrolidine-analog-of-phencyclidine:-1---(phenylcyclohexyl)---33-pyrrolidine,-PCPy,-PHP;-34-(32)-Thiophene-analog-of-phencyclidine-1---[1---(2---thienyl)---cyclohexyl]---35-piperidine,-2---thienylanalog-of-phencyclidine,-TPCP,-TCP;-36-(33)-Thiofuranyl-fentanyl;-37-(34)-(33)-1---[1---(2---thienyl)-cyclohexyl]-pyrrolidine-another-name:-38-TCPy;-39-(35)-(34)-Spores-or-mycelium-capable-of-producing-mushrooms-that-con---40-tain-psilocybin-or-psilocin.-41-(e)-Unless-specifically-excepted-or-unless-listed-in-another-schedule,-42-any-material,-compound,-mixture-or-preparation-which-contains-any-quantity-43-of-the-following-substances-having-a-depressant-effect-on-the-central-ner---44-vous-system,-including-its-salts,-isomers,-and-salts-of-isomers-whenever-the-45-existence-of-such-salts,-isomers,-and-salts-of-isomers-is-possible-within-the-46-specific-chemical-designation:-47-(1)-Bromazolam;-48-(1)-(2)-Clonazolam;-49-(2)-(3)-Diclazepam;-50--10-(3)-(4)-Gamma-hydroxybutyric-acid-(-some-other-names-include-GHB;-gam---1-ma---hydroxybutyrate,-4---hydroxybutyrate;-4---hyroxybutanoic-acid;-sod---2-ium-oxybate;-sodium-oxybutyrate);-3-(4)-(5)-Etizolam;-4-(5)-(6)-Flualprazolam;-5-(6)-(7)-Flubromazolam;-6-(7)-(8)-Flunitrazepam-(also-known-as-R2,-Rohypnol);-7-(8)-(9)-Mecloqualone;-8-(9)-(10)-Methaqualone.-9-(f)-Stimulants.-Unless-specifically-excepted-or-unless-listed-in-an---10-other-schedule,-any-material,-compound,-mixture,-or-preparation-which-con---1-1-tains-any-quantity-of-the-following-substances-having-a-stimulant-effect-on-12-the-central-nervous-system,-including-its-salts,-isomers,-and-salts-of-iso---13-mers:-14-(1)-Amineptine-(7---[(10,11---dihydro---5H---dibenzo[a,d]cyclohepten---5---15-yl)amino]heptanoic-acid)-;-16-(2)-Aminorex-(some-other-names:-(-aminoxaphen-)-,-2---amino---5---phenyl---2---17-oxazoline,-or-4,5---dihydro---5---phenyl---2---oxazolamine),-4,4'---dimethylam---18-inorex-(4,4'---DMAR;-4,5---dihydro---4---methyl---5---(4---methylphenyl)---2---oxazo---19-lamine)-or-(4,5---dihydro---5---phenyl---2---oxazolamine)-;-20-(3)-Cathinone-(-some-other-names:-2---amino---1---phenol---1---propanone,-alp---21-ha---aminopropiophenone,-2---aminopropiophenone-and-norephedrone);-22-(4)-Substituted-cathinones.-Any-compound,-except-bupropion-or-com---23-pounds-listed-under-a-different-schedule,-structurally-derived-from-24-2---aminopropan---1---one-by-substitution-at-the-1---position-with-either-25-phenyl,-naphthyl-or-thiophene-ring-systems,-whether-or-not-the-compound-26-is-further-modified-in-any-of-the-following-ways:-27-i.-By-substitution-in-the-ring-system-to-any-extent-with-alkyl,-28-alkylenedioxy,-alkoxy,-haloalkyl,-hydroxyl-or-halide-sub---29-stituents,-whether-or-not-further-substituted-in-the-ring-system-30-by-one-(1)-or-more-other-univalent-substituents;-31-ii.-By-substitution-at-the-3---position-with-an-acyclic-alkyl-sub---32-stituent;-33-iii.-By-substitution-at-the-2---amino-nitrogen-atom-with-alkyl,-34-dialkyl,-benzyl-or-methoxybenzyl-groups,-or-by-inclusion-of-the-35-2---amino-nitrogen-atom-in-a-cyclic-structure.-36-(5)-Alpha---pyrrolidinoheptaphenone-*-(PV8);-37-(6)-Alpha---pyrrolidinohexanophenone-*-(A---PHP);-38-(7)-4---chloro---alpha---pyrrolidinovalerophenone-*-(4---chloro---a---pvp);-39-(8)-Ethylphenidate;-40-(8)-(9)-Eutylone-(1---(1,3---benzodioxol---5---yl)---2---(ethylamino)bu---41-tan---1---one)-(bk---EBDB)-;-42-(9)-(10)-Fenethylline;-43-(10)-(11)-Mesocarb-(N---phenyl---N'---(3---(1---phenylpropan---2---yl)---1,2,3---oxa---44-diazol---3---ium---5---yl)carbamimidate)-;-45-(11)-(12)-Methcathinone-(-some-other-names:-2---(methyl---amino)---pro---46-piophenone,-alpha---(methylamino)---propiophenone,-N---methylcathin---47-one,-AL---464,-AL---422,-AL---463-and-UR1423);-48-(12)-(13)-Methiopropamine-(N---methyl---1---(thiophen---2---yl)propan---2---49-amine)-;-50--11-(13)-(14)-(+/--)cis---4---methylaminorex-[(+/--)cis---4,5---dihydro---4---meth---1-yl---5---phenyl---2---oxazolamine]-;-2-(14)-(15)-4---methyl---alpha---ethylaminopentiophenone-*-(4---MEAP);-3-(15)-(16)-4'---methyl---alpha---pyrrolidinohexiophenone-*-(MPHP);-4-(16)-(17)-2---(methylamino)---1---(3---methylphenyl)propan---1---one-(3---MMC);-5-(17)-(18)-4---methyl---1---phenyl---2---(pyrrolidine---1---yl)pent---1---one)-(ALPHA---6-PIHP);-7-(18)-(19)-N---benzylpiperazine-(-also-known-as:-BZP,-1---benzylpiper---8-azine);-9-(19)-(20)-N---ethylamphetamine;-10-(20)-(21)-N---ethylhexedrone-*-;-1-1-(21)-(22)-N,N---dimethylamphetamine-(also-known-as:-N,N---alpha---12-trimethyl---benzeneethanamine)-.-13-SECTION-2.-That-Section-37---2707,-Idaho-Code,-be,-and-the-same-is-hereby-14-amended-to-read-as-follows:-15-37---2707.-SCHEDULE-II.-(a)-Schedule-II-shall-consist-of-the-drugs-and-16-other-substances,-by-whatever-official-name,-common-or-usual-name,-chemical-17-name,-or-brand-name-designated,-listed-in-this-section.-18-(b)-Substances,-vegetable-origin-or-chemical-synthesis.-Unless-19-specifically-excepted-or-unless-listed-in-another-schedule,-any-of-the-fol---20-lowing-substances-whether-produced-directly-or-indirectly-by-extraction-21-from-substances-of-vegetable-origin,-or-independently-by-means-of-chemical-22-synthesis,-or-by-a-combination-of-extraction-and-chemical-synthesis:-23-(1)-Opium-and-opiate,-and-any-salt,-compound,-derivative,-or-prepa---24-ration-of-opium-or-opiate,-excluding-apomorphine,-dextrorphan,-nal---25-buphine,-naldemedine,-nalmefene,-naloxegol,-6β---naltexol,-naloxone,-26-naltrexone-,-samidorphan,-and-their-respective-salts,-but-including-the-27-following:-28-1.-i.-Raw-opium;-29-2.-ii.-Opium-extracts;-30-3.-iii.-Opium-fluid-extracts;-31-4.-iv.-Powdered-opium;-32-5.-v.-Granulated-opium;-33-6.-vi.-Tincture-of-opium;-34-7.-vii.-Codeine;-35-8.-viii.-Dihydroetorphine;-36-9.-ix.-Diprenorphine;-37-10.-x.-Ethylmorphine;-38-11.-xi.-Etorphine-hydrochloride;-39-12.-xii.-Hydrocodone;-40-13.-xiii.-Hydromorphone;-41-14.-xiv.-Metopon;-42-15.-xv.-Morphine;-43-xvi.-Noroxymorphone;-44-16.-xvii.-Oripavine;-45-17.-xviii.-Oxycodone;-46-18.-xix.-Oxymorphone;-47-19.-Tapentadol;-48-20.-xx.-Thebaine.-49--12-(2)-Any-salt,-compound,-derivative,-or-preparation-thereof-which-is-1-chemically-equivalent-or-identical-with-any-of-the-substances-referred-2-to-in-paragraph-(1)-of-this-subsection,-except-that-these-substances-3-shall-not-include-the-isoquinoline-alkaloids-of-opium.-4-(3)-Opium-poppy-and-poppy-straw.-5-(4)-Coca-leaves-and-any-salt,-compound,-derivative,-or-preparation-6-of-coca-leaves,-and-any-salt,-compound,-derivative,-or-preparation-7-thereof-which-is-chemically-equivalent-or-identical-with-any-of-these-8-substances,-but-shall-not-include-the-following:-9-1.-i.-Decocainized-coca-leaves-or-extractions-of-coca-leaves,-10-which-extractions-do-not-contain-cocaine;-or-ecgonine;-or-1-1-2.-ii.-[-1-2-3-I]ioflupane.-12-(5)-Benzoylecgonine.-13-(6)-Methylbenzoylecgonine-(-Cocaine-,---its-salts,-optical-and-geometric-14-isomers,-and-salts-of-optical-and-geometric-isomers-)-.-15-(7)-Concentrate-of-poppy-straw-(the-crude-extract-of-poppy-straw-in-liq---16-uid,-solid-or-powder-form-that-contains-the-phenanthrine-alkaloids-of-17-the-opium-poppy).-18-(c)-Any-of-the-following-opiates,-including-their-isomers,-esters,-19-ethers,-salts,-and-salts-of-isomers,-whenever-the-existence-of-these-iso---20-mers,-esters,-ethers-and-salts-is-possible-within-the-specific-chemical-21-designation,-unless-specifically-excepted-or-unless-listed-in-another-22-schedule:-23-(1)-Alfentanil;-24-(2)-Alphaprodine;-25-(3)-Anileridine;-26-(4)-Bezitramide;-27-(5)-Bulk-Dextropropoxyphene-(nondosage-forms);-28-(6)-Carfentanil;-29-(7)-Dihydrocodeine;-30-(8)-Diphenoxylate;-31-(9)-Fentanyl;-32-(10)-Isomethadone;-33-(11)-Levo---alphacetylmethadol-(-also-known-as-levo---alpha---acetylmet---34-hadol,-levomethadyl-acetate,-LAAM);-35-(12)-Levomethorphan;-36-(13)-Levorphanol;-37-(14)-Metazocine;-38-(15)-Methadone;-39-(16)-Methadone-----Intermediate,-4---cyano---2---dimethylamino---4,-4---diphenyl-40-butane;-41-(17)-Moramide-----Intermediate,-2---methyl---3---morpholino---1,-1---diphenyl-42-propane---carboxylic-acid;-43-(18)-Norfentanyl-(N---phenyl---N---(piperidin---4---yl)-propionamide);-44-(19)-(18)-Oliceridine;-45-(20)-(19)-Pethidine-(meperidine);-46-(21)-(20)-Pethidine-----Intermediate-----A,-4---cyano---1---methyl---4---phenyl---47-piperidine;-48-(22)-(21)-Pethidine-----Intermediate-----B,-ethyl---4---phenylpiperid---49-ine---4---carboxylate;-50--13-(23)-(22)-Pethidine-----Intermediate-----C,-1---methyl---4---phenylpiperid---1-ine---4---carboxylic-acid;-2-(24)-(23)-Phenazocine;-3-(25)-(24)-Piminodine;-4-(26)-(25)-Racemethorphan;-5-(27)-(26)-Racemorphan;-6-(28)-(27)-Remifentanil;-7-(29)-(28)-Sufentanil-.-;-8-(29)-Tapentadol;-9-(30)-Thiafentanil.-10-(d)-Stimulants.-Unless-specifically-excepted-or-unless-listed-in-an---1-1-other-schedule,-any-material,-compound,-mixture,-or-preparation-which-con---12-tains-any-quantity-of-the-following-substances-having-a-stimulant-effect-on-13-the-central-nervous-system:-14-(1)-Amphetamine,-its-salts,-optical-isomers,-and-salts-of-its-optical-15-isomers;-16-(2)-Lisdexamfetamine-,-its-salts,-isomers,-and-salts-of-its-isomers-;-17-(3)-Methamphetamine,-its-salts,-isomers,-and-salts-of-its-isomers;-18-(4)-Phenmetrazine-and-its-salts;-19-(5)-Methylphenidate.-20-(e)-Depressants.-Unless-specifically-excepted-or-unless-listed-in-an---21-other-schedule,-any-material,-compound,-mixture,-or-preparation-which-con---22-tains-any-quantity-of-the-following-substances-having-a-depressant-effect-on-23-the-central-nervous-system,-including-its-salts,-isomers,-and-salts-of-iso---24-mers,-whenever-the-existence-of-such-salts,-isomers,-and-salts-of-isomers-is-25-possible-within-the-specific-chemical-designation:-26-(1)-Amobarbital;-27-(2)-Glutethimide;-28-(3)-Pentobarbital;-29-(4)-Phencyclidine;-30-(5)-Secobarbital.-31-(f)-Hallucinogenic-substances.-32-(1)-Nabilone-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-(another-name-for-nabilone:-33-(+/--)---trans---3---(1,1---dimethylheptyl)---6,6a,7,8,10,10a---hexahydro---1---hy---34-droxy---6,6---dimethyl---9H---dibenzo[b,d]pyran---9---one)-(21-CFR-1308.12-(f))-.-35-(g)-Immediate-precursors.-Unless-specifically-excepted-or-unless-36-listed-in-another-schedule,-any-material,-compound,-mixture,-or-preparation-37-which-contains-any-quantity-of-the-following-substances:-38-(1)-Immediate-precursor-to-amphetamine-and-methamphetamine:-39-(a)-i.-Anthranilic-acid;-40-(b)-ii.-Ephedrine;-41-(c)-iii.-Lead-acetate;-42-(d)-iv.-Methylamine;-43-(e)-v.-Methyl-formamide;-44-(f)-vi.-N---methylephedrine;-45-(g)-vii.-Phenylacetic-acid;-46-(h)-viii.-Phenylacetone-(phenyl---2---propanone,-P2P)-;-47-(i)-ix.-Phenylpropanolamine;-48-(j)-x.-Pseudoephedrine.-49--14-Except-that-any-combination-or-compound-containing-ephedrine,-or-any-of-1-its-salts-and-isomers,-or-phenylpropanolamine-or-its-salts-and-isomers,-2-or-pseudoephedrine,-or-any-of-its-salts-and-isomers-which-is-prepared-3-for-dispensing-or-over---the---counter-distribution-is-not-a-controlled-4-substance-for-the-purpose-of-this-section,-unless-such-substance-is-pos---5-sessed,-delivered,-or-possessed-with-intent-to-deliver-to-another-with-6-the-intent-to-manufacture-methamphetamine,-amphetamine-or-any-other-7+formulas.+In+addition+to+updating+the+schedules,+the+bill+amends+Article+III+by+revising+requirements+forcontrolledsubstance-in-violation-of-section-37---2732,-Idaho-Code.-For-8-purposes-of-this-provision,-the-requirements-of-the-uniform-controlled-9-substances-act-shall-not-apply-to-a-manufacturer,-wholesaler-or-re---10-tailer-of-over---the---counter-products-containing-the-listed-substances-1-1-unless-such-person-possesses,-delivers,-or-possesses-with-intent-to-12-deliver-to-another-the-over---the---counter-product-with-intent-to-manufac---13-ture-a-controlled-substance.-14-(2)-Immediate-precursors-to-phencyclidine-(PCP):-15-(a)-i.-1---phenylcyclohexylamine;-16-(b)-ii.-1---piperidinocyclohexanecarbonitrile-(PCC).-17-(3)-Immediate-precursor-s-to-fentanyl:-18-i.-4---anilino---N---phenethyl---4---piperidine-(ANPP)-.-;-19-ii.-Norfentanyl.-20-SECTION-3.-That-Section-37---2709,-Idaho-Code,-be,-and-the-same-is-hereby-21-amended-to-read-as-follows:-22-37---2709.-SCHEDULE-III.-(a)-Schedule-III-shall-consist-of-the-drugs-and-23-other-substances,-by-whatever-official-name,-common-or-usual-name,-chemical-24-name,-or-brand-name-designated,-listed-in-this-section.-25-(b)-Stimulants.-Unless-specifically-excepted-or-unless-listed-in-an---26-other-schedule,-any-material,-compound,-mixture,-or-preparation-which-con---27-tains-any-quantity-of-the-following-substances-having-a-stimulant-effect-on-28-the-central-nervous-system,-including-its-salts,-isomers,-(whether-optical-,-29-positional,-or-geometric),-and-salts-of-such-isomers-whenever-the-existence-30-of-such-salts,-isomers,-and-salts-of-isomers-is-possible-within-the-specific-31-chemical-designation:-32-(1)-Those-compounds,-mixtures,-or-preparations-in-dosage-unit-form-con---33-taining-any-stimulant-substances-listed-in-schedule-II-which-compounds,-34-mixtures,-or-preparations-were-listed-as-excepted-compounds-under-21-35-CFR-1308.32,-and-any-other-drug-of-the-quantitative-composition-shown-in-36-that-list-for-those-drugs-or-which-is-the-same-except-that-it-contains-a-37-lesser-quantity-of-controlled-substances.-38-(2)-Benzphetamine;-39-(3)-Chlorphentermine;-40-(4)-Clortermine;-41-(5)-Phendimetrazine.-42-(c)-Depressants.-Unless-listed-in-another-schedule,-any-material,-com---43-pound,-mixture,-or-preparation-which-contains-any-quantity-of-the-following-44-substances-having-a-potential-for-abuse-associated-with-a-depressant-effect-45-on-the-central-nervous-system:-46-(1)-Any-compound,-mixture-or-preparation-containing-the-following-sub---47-stances-or-any-salt-thereof-and-one-(1)-or-more-other-active-medicinal-48-ingredients-that-are-not-listed-in-any-schedule-:-49--15-i.-Amobarbital;-1-ii.-Secobarbital;-2-iii.-Pentobarbital-or-any-salt-thereof-and-one-(1)-or-more-other-3-active-medicinal-ingredients-which-are-not-listed-in-any-schedule-.-4-(2)-Any-suppository-dosage-form-containing-the-following-substances-or-5-any-salt-of-any-of-these-drugs-and-approved-by-the-food-and-drug-adminis---6-tration-for-marketing-only-as-a-suppository-:-7-i.-Amobarbital;-8-ii.-Secobarbital;-9-iii.-Pentobarbital-or-any-salt-of-any-of-these-drugs-and-approved-10-by-the-Food-and-Drug-Administration-for-marketing-only-as-a-suppos---1-1-itory-.-12-(3)-Any-substance-which-contains-any-quantity-of-a-derivative-of-barbi---13-turic-acid-or-any-salt-thereof,-including,-but-not-limited-to:-14-i.-Aprobarbital;-15-ii.-Butabarbital-(secbutabarbital);-16-iii.-Butalbital,-excluding-drug-products-exempted-by-the-federal-17-drug-enforcement-administration-(DEA);-18-iv.-Butobarbital-(butethal);-19-v.-Talbutal;-20-vi.-Thiamylal;-21-vii.-Thiopental;-22-viii.-Vinbarbital.-23-(4)-Chlorhexadol;-24-(5)-Embutramide;-25-(6)-Any-drug-product-containing-gamma-hydroxybutyric-acid-(GHB)-,-in---26-cluding-its-salts,-isomers,-and-salts-of-isomers,-for-which-an-applica---27-tion-is-approved-under-section-505-of-the-federal-food,-drug,-and-cos---28-metic-act;-29-(7)-Ketamine,-its-salts,-isomers,-and-salts-of-isomers---30-7285.-(Some-other-names-for-ketamine:-(+/--)---2---(2---chlorophenyl)---2---31-(methylamino)---cyclohexanone)-.-32-(8)-Lysergic-acid;-33-(9)-Lysergic-acid-amide-(LSA,-LAA)-;-34-(10)-Methyprylon;-35-(11)-Perampanel,-and-its-salts,-isomers-and-salts-of-isomers;-36-(12)-Sulfondiethylmethane;-37-(13)-Sulfonethylmethane;-38-(14)-Sulfonmethane;-39-(15)-Tiletamine-and-zolazepam-or-any-salt-thereof.-40-(d)-Nalorphine.-41-(e)-Narcotic-drugs.-Unless-specifically-excepted-or-unless-listed-in-42-another-schedule:-43-(1)-Any-material,-compound,-mixture,-or-preparation-containing-limited-44-quantities-of-any-of-the-following-narcotic-drugs,-or-any-salts-thereof:-45-(i)-i.-Not-more-than-1.8-grams-of-codeine,-or-any-of-its-salts,-46-per-100-milliliters-or-not-more-than-90-milligrams-per-dosage-unit,-47-with-an-equal-or-greater-quantity-of-an-isoquinoline-alkaloid-of-48-opium;-49--16-(ii)-ii.-Not-more-than-1.8-grams-of-codeine,-or-any-of-its-salts,-1-per-100-milliliters-or-not-more-than-90-milligrams-per-dosage-unit,-2-with-one-(1)-or-more-active,-nonnarcotic-ingredients-in-recognized-3-therapeutic-amounts;-4-(iii)-iii.-Not-more-than-1.8-grams-of-dihydrocodeine,-or-any-of-5-its-salts,-per-100-milliliters-or-not-more-than-90-milligrams-per-6-dosage-unit,-with-one-(1)-or-more-active,-nonnarcotic-ingredients-7-in-recognized-therapeutic-amounts;-8-(iv)-iv.-Not-more-than-300-milligrams-of-ethylmorphine,-or-any-of-9-its-salts,-per-100-milliliters-or-not-more-than-15-milligrams-per-10-dosage-unit,-with-one-(1)-or-more-active,-nonnarcotic-ingredients-1-1-in-recognized-therapeutic-amounts;-12-(v)-v.-Not-more-than-500-milligrams-of-opium-per-100-milliliters-13-or-per-100-grams,-or-not-more-than-25-milligrams-per-dosage-unit,-14-with-one-(1)-or-more-active,-nonnarcotic-ingredients-in-recognized-15-therapeutic-amounts;-16-(vi)-vi.-Not-more-than-50-milligrams-of-morphine,-or-any-of-its-17-salts,-per-100-milliliters-or-per-100-grams-with-one-(1)-or-more-ac---18-tive,-nonnarcotic-ingredients-in-recognized-therapeutic-amounts.-19-(2)-Any-material,-compound,-mixture,-or-preparation-containing-any-of-20-the-following-narcotic-drugs-or-their-salts,-as-set-forth-below:-21-(i)-i.-Buprenorphine.-22-(ii)-ii.-[Reserved].-23-(f)-Anabolic-steroids-and-human-growth-hormones.-Any-drug-or-hormonal-24-substance,-chemically-and-pharmacologically-related-to-testosterone-(other-25-than-estrogens,-progestins-and-corticosteroids)-that-promotes-muscle-growth-26-including-any-salt,-ester-or-isomer-of-a-drug-or-substance-listed-in-this-sub---27-section,-if-that-salt,-ester-or-isomer-promotes-muscle-growth.-28-(1)-13beta---ethyl---17beta---hydroxygon---4---en---3---one;-29-(2)-17alpha---methyl---3alpha,-17beta---dihydroxy---5alpha---androstane;-30-(3)-17alpha---methyl---3beta,-17beta---dihydroxy---5alpha---androstane;-31-(4)-17alpha---methyl---3beta,-17beta---dihydroxyandrost---4---ene;-32-(5)-17alpha---methyl---4---hydroxynandrolone;-33-(6)-17alpha---methyl---5alpha---androstan---17beta---ol;-34-(7)-17alpha---methyl---androst---2---ene---3,17beta---diol;-35-(8)-17alpha---methyl---androsta---1,4---diene---3,17beta---diol;-36-(9)-17alpha---methyl---androstan---3---hydroxyimine---17beta---ol;-37-(10)-17alpha---methyl---delta1---dihydrotestosterone;-38-(11)-17beta---hydroxy---androstano[-2,3-3,2---c]isoxazole;-39-(12)-17beta---hydroxy---androstano[2,3---d]isoxazole;-40-(13)-18alpha---homo---3---hydroxy---estra---2,5(10)---dien---17---one;-41-(14)-19---nor---4---androstenediol;-42-(15)-19---nor---4---androstenedione;-43-(16)-19---nor---4,9(10)---androstadienedione;-44-(17)-19---nor---5---androstenediol;-45-(18)-19---nor---5---androstenedione;-46-(19)-1---androstenediol;-47-(20)-1---androstenedione;-48-(21)-2alpha,17alpha---dimethyl---17beta---hydroxy---5beta---androstan---3---one;-49--17-(22)-2alpha,3alpha---epithio---17alpha---methyl---5alpha---androstan---17beta---1-ol;-2-(23)-[3,2---c]furazan---5alpha---androstan---17beta---ol;-3-(24)-[3,2---c]pyrazole---androst---4---en---17beta---ol;-4-(25)-3alpha,17beta---dihydroxy---5alpha---androstane;-5-(26)-3beta,17beta---dihydroxy---5alpha---androstane;-6-(27)-3beta---hydroxy---estra---4,9,11---trien---17---one;-7-(28)-4---androstenediol;-8-(29)-4---androstenedione;-9-(30)-4---chloro---17alpha---methyl---androsta---1,4---diene---3,17beta---diol;-10-(31)-4---chloro---17alpha---methyl---androst---4---ene---3beta,17beta---diol;-1-1-(32)-4---chloro---17alpha---methyl---17beta---hydroxy---androst---4---en---3---one;-12-(33)-4---chloro---17alpha---methyl---17beta---hydroxy---androst---4---ene---3,11---13-dione;-14-(34)-4---hydroxy---19---nortestosterone;-15-(35)-4---hydroxy---androst---4---ene---3,17---dione;-16-(36)-4---hydroxytestosterone;-17-(37)-5alpha---androstan---3,17---dione;-18-(38)-5alpha---androstan---3,6,17---trione;-19-(39)-5---androstenediol;-20-(40)-5---androstenedione;-21-(41)-6alpha---methyl---androst---4---ene---3,17---dione;-22-(42)-6---bromo---androsta---1,4---diene---3,17---dione;-23-(43)-6---bromo---androstan---3,17---dione;-24-(44)-Androstenedione;-25-(45)-Bolasterone;-26-(46)-Boldenone;-27-(47)-Boldione;-28-(48)-Calusterone;-29-(49)-Chlorotestosterone-(4---chlorotestosterone);-30-(50)-Clostebol;-31-(51)-Dehydrochlormethyltestosterone;-32-(52)-Delta1---dihydrotestosterone-(1---testosterone)-;-33-(53)-Desoxymethyltestosterone-(madol)-;-34-(54)-Dihydrotestosterone-(4---dihydrotestosterone);-35-(55)-Drostanolone;-36-(56)-Estra---4,9,11---triene---3,17---dione;-37-(57)-Ethylestrenol;-38-(58)-Fluoxymesterone;-39-(59)-Formebulone-Formebolone-;-40-(60)-Furazabol;-41-(61)-Human-growth-hormones;-42-(62)-Mestanolone;-43-(63)-Mesterolone;-44-(64)-Methandienone;-45-(65)-Methandranone;-46-(66)-Methandriol;-47-(67)-Methandrostenolone;-48-(68)-Methasterone-(2a,-17a---dimethyl---5a---androstan---17β---ol---3---one)-;-49-(69)-Methenolone;-50--18-(70)-Methyldienolone;-1-(71)-Methyltestosterone;-2-(72)-Methyltrienolone;-3-(73)-Mibolerone;-4-(74)-Nandrolone;-5-(75)-Norbolethone;-6-(76)-Norclostebol;-7-(77)-Norethandrolone;-8-(78)-Normethandrolone;-9-(79)-Oxandrolone;-10-(80)-Oxymesterone;-1-1-(81)-Oxymetholone;-12-(82)-Prostanozol-(17β---hydroxy---5a---androstano[3,2---c]pyrazole)-;-13-(83)-Stanolone;-14-(84)-Stanozolol;-15-(85)-Stenbolone;-16-(86)-Testolactone;-17-(87)-Testosterone;-18-(88)-Testosterone-cypionate;-19-(89)-Testosterone-enanthate;-20-(90)-Testosterone-propionate;-21-(91)-Tetrahydrogestrinone;-22-(92)-Trenbolone.-23-Anabolic-steroids-that-are-expressly-intended-for-administration-24-through-implants-or-injection-to-cattle-or-other-nonhuman-species,-and-that-25-are-approved-by-the-federal-Food-and-Drug-Administration-for-such-use,-shall-26-not-be-classified-as-controlled-substances-under-this-act-and-shall-not-be-27-governed-by-its-provisions.-28-In-addition-to-the-penalties-prescribed-in-article-IV-of-the-uniform-29-controlled-substances-act,-any-person-shall-be-guilty-of-a-felony-who-pre---30-scribes,-dispenses,-supplies,-sells,-delivers,-manufactures-or-possesses-31-with-the-intent-to-prescribe,-dispense,-supply,-sell,-deliver-or-manufac---32-ture-anabolic-steroids-or-any-other-human-growth-hormone-for-purposes-of-33-enhancing-performance-in-an-exercise,-sport-or-game-or-hormonal-manipulation-34-intended-to-increase-muscle-mass,-strength-or-weight-without-a-medical-ne---35-cessity-as-determined-by-a-physician.-36-(g)-Hallucinogenic-substances.-37-(1)-Dronabinol-(synthetic)-in-sesame-oil-and-encapsulated-in-a-soft-38-gelatin-capsule-in-the-federal-Food-and-Drug-Administration-ap---39-proved-product-----7369.-(Some-other-names-for-dronabinol:-(6aR---40-trans)---6a,7,8,10a---tetrahydro---6,6,9---trimethyl---3---pentyl---6H---dibenzo-41-[b,d]pyran---1---ol-or-(--)---delta---9---(trans)---tetrahydrocannabinol)-.-42-(h)-The-board-may-except-by-rule-any-compound,-mixture,-or-preparation-43-containing-any-stimulant-or-depressant-substance-listed-in-subsection-(b)-44-or-(c)-of-this-section-from-the-application-of-all-or-any-part-of-this-act-if-45-the-compound,-mixture,-or-preparation-contains-one-(1)-or-more-active-medic---46-inal-ingredients-not-having-a-stimulant-or-depressant-effect-on-the-central-47-nervous-system,-and-if-the-admixtures-are-included-therein-in-combinations,-48-quantity,-proportion,-or-concentration-that-vitiate-the-potential-for-abuse-49--19-of-the-substances-which-have-a-stimulant-or-depressant-effect-on-the-central-1-nervous-system.-2-SECTION-4.-That-Section-37---2711,-Idaho-Code,-be,-and-the-same-is-hereby-3-amended-to-read-as-follows:-4-37---2711.-SCHEDULE-IV.-(a)-Schedule-IV-shall-consist-of-the-drugs-and-5-other-substances,-by-whatever-official-name,-common-or-usual-name,-chemical-6-name,-or-brand-name-designated,-listed-in-this-section.-7-(b)-Narcotic-drugs.-Unless-specifically-excepted-or-unless-listed-in-8-another-schedule,-any-material,-compound,-mixture,-or-preparation-contain---9-ing-any-of-the-following-narcotic-drugs,-or-their-salts-calculated-as-the-10-free-anhydrous-base-or-alkaloid,-in-limited-quantities-as-set-forth-below:-1-1-(1)-No-more-than-1-milligram-of-difenoxin-and-not-less-than-25-micro---12-grams-of-atropine-sulfate-per-dosage-unit;-13-(2)-Dextropropoxyphene-(alpha---(+)---4---dimethylamino---1,-2---diphenyl---14-3---methyl---2---propionoxybutane);-15-(3)-2---[(dimethylamino)methyl]---1---(3---methoxyphenyl)cyclohexanol-(in---16-cluding-tramadol)-Tramadol-,-including-its-salts,-optical-and-geometric-17-isomers,-and-salts-of-isomers.-18-(c)-Depressants.-Unless-specifically-excepted-or-unless-listed-in-an---19-other-schedule,-any-material,-compound,-mixture,-or-preparation-which-con---20-tains-any-quantity-of-the-following-substances,-including-its-salts,-iso---21-mers,-and-salts-of-isomers-whenever-the-existence-of-such-salts,-isomers,-and-22-salts-of-isomers-is-possible-within-the-specific-chemical-designation:-23-(1)-Alfaxalone-5[alpha]---pregnan---3[alpha]---ol---11,20---dione;-24-(2)-Alprazolam;-25-(3)-Barbital;-26-(4)-Brexanolone-(allopregnanolone);-27-(4)-(5)-Bromazepam;-28-(5)-(6)-Camazepam;-29-(6)-(7)-Carisoprodol;-30-(7)-(8)-Chloral-betaine;-31-(8)-(9)-Chloral-hydrate;-32-(9)-(10)-Chlordiazepoxide;-33-(10)-(11)-Clobazam;-34-(11)-(12)-Clonazepam;-35-(12)-(13)-Clorazepate;-36-(13)-(14)-Clotiazepam;-37-(14)-(15)-Cloxazolam;-38-(15)-(16)-Daridorexant;-39-(16)-(17)-Delorazepam;-40-(17)-(18)-Diazepam;-41-(18)-(19)-Dichloralphenazone;-42-(19)-(20)-Estazolam;-43-(20)-(21)-Ethchlorvynol;-44-(21)-(22)-Ethinamate;-45-(22)-(23)-Ethyl-loflazepate;-46-(23)-(24)-Fludiazepam;-47-(24)-(25)-Flurazepam;-48-(25)-(26)-Fospropofol;-49--20-(26)-(27)-Halazepam;-1-(27)-(28)-Haloxazolam;-2-(28)-(29)-Ketazolam;-3-(29)-(30)-Lemborexant;-4-(30)-(31)-Loprazolam;-5-(31)-(32)-Lorazepam;-6-(32)-(33)-Lormetazepam;-7-(33)-(34)-Mebutamate;-8-(34)-(35)-Medazepam;-9-(35)-(36)-Meprobamate;-10-(36)-(37)-Methohexital;-1-1-(37)-(38)-Methylphenobarbital-(mephobarbital);-12-(38)-(39)-Midazolam;-13-(39)-(40)-Nimetazepam;-14-(40)-(41)-Nitrazepam;-15-(41)-(42)-Nordiazepam;-16-(42)-(43)-Oxazepam;-17-(43)-(44)-Oxazolam;-18-(44)-(45)-Paraldehyde;-19-(45)-(46)-Petrichloral;-20-(46)-(47)-Phenobarbital;-21-(47)-(48)-Pinazepam;-22-(48)-(49)-Prazepam;-23-(49)-(50)-Quazepam;-24-(50)-(51)-Remimazolam;-25-(51)-Serdexmethylpheniate;-26-(52)-Suvorexant;-27-(53)-Temazepam;-28-(54)-Tetrazepam;-29-(55)-Triazolam;-30-(56)-Zaleplon;-31-(57)-Zolpidem;-32-(58)-Zopiclone;-33-(59)-Zuranolone.-34-(d)-Fenfluramine-----Any-material,-compound,-mixture,-or-preparation-35-which-contains-any-quantity-of-the-following-substances,-including-its-36-salts,-isomers-(whether-optical,-position,-or-geometric),-and-salts-of-such-37-isomers,-whenever-the-existence-of-such-salts,-isomers,-and-salts-of-isomers-38-is-possible:-39-(1)-Dexfenfluramine;-40-(2)-Fenfluramine.-41-(e)-Stimulants.-Unless-specifically-excepted-or-unless-listed-in-an---42-other-schedule,-any-material,-compound,-mixture,-or-preparation-which-con---43-tains-any-quantity-of-the-following-substances-having-a-stimulant-effect-on-44-the-central-nervous-system,-including-its-salts,-isomers-(whether-optical,-45-position,-or-geometric),-and-salts-of-such-isomers-whenever-the-existence-46-of-such-salts,-isomers,-and-salts-of-isomers-is-possible-within-the-specific-47-chemical-designation:-48-(1)-Cathine-((+)---norpseudoephedrine);-49-(2)-Diethylpropion;-50--21-(3)-Fencamfamin;-1-(4)-Fenproporex;-2-(5)-Lorcaserin;-3-(6)-Mazindol;-4-(7)-Mefenorex;-5-(8)-Modafinil;-6-(9)-Pemoline-(including-organometallic-complexes-and-chelates-7-thereof);-8-(10)-Phentermine;-9-(11)-Pipradrol;-10-(12)-Serdexmethylpheniate;-1-1-(12)-(13)-Sibutramine;-12-(13)-(14)-SPA-((--)---1---dimethylamino---1,2---diphenylethane);-13-(14)-(15)-Solriamfetol-(2---amino---3---phenylpropyl-carbamata;-benzene---14-propanol,-beta---amino--,-carbamate(ester))-.-15-(f)-Other-substances.-Unless-specifically-excepted,-or-unless-listed-16-in-another-schedule,-any-material,-compound,-mixture-or-preparation-which-17-contains-any-quantity-of-the-following-substances,-including-its-salts:-18-(1)-Brexanolone-(3A---hydroxy---5A---pregnan---20---one),-allopregnanolone;-19-(2)-(1)-Butorphanol-(including-its-optical-isomers);-20-(3)-(2)-Eluxadoline-(5---[[[(2S)---2---amino---3---[4---aminocarbonyl)---2,6---21-dimethylphenyl]---1---oxopropyl][(1S)---1---(4---phenyl---1H---imidazol---2---22-yl)ethyl]amino]methyl]---2---methoxybenzoic-acid)-(including-its-optical-23-isomers-)-and-its-salts,-isomers,-and-salts-of-isomers-)-;-24-(4)-(3)-Pentazocine.-25-(g)-The-board-may-except,-by-rule,-any-compound,-mixture,-or-prepara---26-tion-containing-any-depressant-substance-listed-in-subsection-(c)-of-this-27-section-from-the-application-of-all-or-any-part-of-this-act-if-the-compound,-28-mixture,-or-preparation-contains-one-(1)-or-more-active-medicinal-ingredi---29-ents-not-having-a-depressant-effect-on-the-central-nervous-system,-and-if-the-30-admixtures-are-included-therein-in-combinations,-quantity,-proportion,-or-31-concentration-that-vitiate-the-potential-for-abuse-of-the-substances-which-32-have-a-depressant-effect-on-the-central-nervous-system.-33-SECTION-5.-That-Section-37---2713,-Idaho-Code,-be,-and-the-same-is-hereby-34-amended-to-read-as-follows:-35-37---2713.-SCHEDULE-V.-(a)-Schedule-V-shall-consist-of-the-drugs-and-36-other-substances,-by-whatever-official-name,-common-or-usual-name,-chemical-37-name,-or-brand-name-designated,-listed-in-this-section.-38-(b)-Narcotic-drugs.-Unless-specifically-excepted-or-unless-listed-in-39-another-schedule,-any-material,-compound,-mixture,-or-preparation-contain---40-ing-any-of-the-following-narcotic-drugs-and-their-salts,-as-set-forth-below.-41-(c)-Narcotic-drugs-containing-nonnarcotic-active-medicinal-ingredi---42-ents.-Any-compound,-mixture,-or-preparation-containing-any-of-the-follow---43-ing-limited-quantities-of-narcotic-drugs-or-salts-thereof,-which-shall-in---44-clude-one-(1)-or-more-nonnarcotic-active-medicinal-ingredients-in-sufficient-45-proportion-to-confer-upon-the-compound,-mixture,-or-preparation,-valuable-46-medicinal-qualities-other-than-those-possessed-by-the-narcotic-drug-alone:-47-(1)-Not-more-than-200-milligrams-of-codeine-per-100-milliliters-or-per-48-100-grams;-49--22-(2)-Not-more-than-100-milligrams-of-dihydrocodeine-per-100-milliliters-1-or-per-100-grams;-2-(3)-Not-more-than-100-milligrams-of-ethylmorphine-per-100-milliliters-3-or-per-100-grams;-4-(4)-Not-more-than-2.5-milligrams-of-diphenoxylate-and-not-less-than-25-5-micrograms-of-atropine-sulfate-per-dosage-unit;-6-(5)-Not-more-than-100-milligrams-of-opium-per-100-milliliters-or-per-100-7-grams;-8-(6)-Not-more-than-0.5-milligrams-difenoxin-and-not-less-than-25-micro---9-grams-of-atropine-sulfate-per-dosage-unit.-10-(d)-Other-substances.-Unless-specifically-excepted-or-unless-listed-1-1-in-another-schedule,-any-material,-compound,-mixture-or-preparation-which-12-contains-any-quantity-of-the-following-substances,-including-its-salts:-13-(1)-Brivaracetam-(-(2S)---2---[(4R)---2---oxo---4---propylpyrrolidin---1---yl]bu---14-tanamide)-(also-referred-to-as-BRV;-UCB---34714;-Briviact)-(including-its-15-salts);-16-(2)-Cenobamate-[(1R)---1---(2---chlorophenyl)---2---(tetrazol---2---yl)ethyl]car---17-bamate-;-18-(3)-Ezogabine-[N---[2---amino---4---(4---fluorobenzylamino)---phenyl]---carbamic-19-acid-ethyl-ester]---2779-;-20-(4)-Ganaxolone-(3---alpha---hydroxy---3---beta---methyl---5---alpha---preg---21-nan---20---one)-;-22-(5)-Lacosamide;-23-(6)-Lasmiditan-[2,4,6---trifluoro---N---(6---(1---methylpiperidine---4---car---24-bonyl)pyridine---2---yl)benzamide]-;-25-(7)-Pregabalin;-26-(8)-Pyrovalerone.-27-SECTION-6.-That-Section-37---2716,-Idaho-Code,-be,-and-the-same-is-hereby-28-amended-to-read-as-follows:-29-37---2716.-REGISTRATION-REQUIREMENTS.-(a)-Every-person-who-manufac---30-tures,-distributes,-prescribes,-administers,-or-conducts-research-with-any-31-controlled-substance-within-this-state-shall-obtain-annually-biennially-a-32-registration-issued-by-the-board-in-accordance-with-Idaho-law.-All-drug-out---33-lets-with-a-valid-license-or-registration-under-chapter-17,-title-54,-Idaho-34-Code,-are-exempt-from-obtaining-a-separate-controlled-substance-registra---35-tion.-36-(b)-Every-dispenser-and-prescriber,-except-veterinarians,-shall-also-37-register-with-the-division-to-obtain-online+registrations+andaccessto-the-controlled-sub---38-stances-prescriptions-database.-39-(c)-Persons-registered-by-the-board-under-this-chapter-may-possess,-40-manufacture,-distribute,-dispense,-prescribe,-administer,-or-conduct-re---41-search-with-those-substances-to-the-extent-authorized-by-their-registration-42-and-licensing-entity-and-in-conformity-with-the-other-provisions-of-this-43-chapter.-44-(d)-The-following-persons-need-not-register-and-may-lawfully-possess-45-controlled-substances-under-this-chapter:-46-(1)-An-agent-or-employee-of-any-person-registered-pursuant-to-this-chap---47-ter,-if-he-is-acting-in-the-usual-course-of-his-business-or-employment;-48--23-(2)-A-common-or-contract-carrier-or-warehouseman,-or-an-employee-1-thereof,-whose-possession-of-any-controlled-substance-is-in-the-usual-2-course-of-business-or-employment;-3-(3)-An-ultimate-user-or-a-person-in-possession-of-any-controlled-sub---4-stance-pursuant-to-a-lawful-order-of-a-practitioner-or-in-lawful-posses---5-sion-of-a-schedule-V-substance.-6-(e)-A-separate-registration-is-required-at-each-principal-place-of-7-business-or-professional-practice-where-the-applicant-manufactures,-dis---8-tributes,-administers,-dispenses,-or-conducts-research-with-controlled-9-substances,-except-a-separate-registration-is-not-required-under-this-chap---10-ter-for-practitioners-engaging-in-research-with-nonnarcotic-controlled-1-1-substances-in-schedules-II-through-IV-where-the-practitioner-is-already-reg---12-istered-under-this-chapter-in-another-capacity.-13-(f)-Practitioners-registered-under-federal-law-to-conduct-research-14-with-schedule-I-substances-may-conduct-research-with-schedule-I-substances-15-within-this-state-upon-registering-in-Idaho-and-furnishing-the-board-with-16-evidence-of-the-practitioner's-federal-registration.-17-(g)-The-board-may-inspect-the-establishment-of-a-registrant-or-appli---18-cant-for-registration-in-accordance-with-Idaho-law.-19-SECTION-7.-That-Section-37---2717,-Idaho-Code,-be,-and-the-same-is-hereby-20-amended-to-read-as-follows:-21-37---2717.-REGISTRATION.-The-board-shall-register-an-applicant-to-man---22-ufacture,-prescribe,-administer,-dispense,-distribute-or-conduct-research-23-with-controlled-substances-included-in-sections-37---2705,-37---2707,-37---2709,-24-37---2711-and-37---2713,-Idaho-Code,-unless-it-determines-that-the-issuance-of-25-that-registration-would-be-inconsistent-with-the-public-interest.-In-deter---26-mining-the-public-interest,-the-board-shall-consider-the-following-factors:-27-(a)-Maintenance-of-effective-controls-against-diversion-of-controlled-28-substances-into-other-than-legitimate-medical,-scientific,-or-industrial-29-channels;-30-(b)-Compliance-with-applicable-state-and-local-law;-31-(c)-Any-convictions-of-the-applicant-under-any-federal-and-state-laws-32-relating-to-any-controlled-substance;-33-(d)-Past-experience-Experience-in-the-manufacture,-dispensing,-34-prescribing,-administering,-research-or-distribution-of-controlled-sub---35-stances,-and-the-existence-in-the-applicant's-establishment-of-effective-36-controls-against-diversions;-37-(e)-Furnishing-by-the-applicant-of-false-or-fraudulent-material-in-any-38-application-filed-under-this-chapter;-39-(f)-Restriction,-suspension-or-revocation-of-the-applicant's-federal-40-registration;-and-41-(g)-Any-other-factors-relevant-to-and-consistent-with-the-public-health-42-and-safety.-43-SECTION-8.-That-Section-37---2718,-Idaho-Code,-be,-and-the-same-is-hereby-44-amended-to-read-as-follows:-45--24-37---2718.-DISCIPLINE.-(a)-A-registration-under-section-37---2717,-Idaho-1-Code,-may-be-restricted,-suspended-or-revoked-by-the-board-upon-a-finding-2-that-the-registrant:-3-(1)-Has-furnished-false-or-fraudulent-material-information-in-any-ap---4-plication-filed-under-this-act;-5-(2)-Has-been-found-guilty-of-a-felony-or-misdemeanor-under-any-state-or-6-federal-law-relating-to-any-controlled-substance;-7-(3)-Has-had-his-federal-registration-restricted,-suspended-or-revoked;-8-or-9-(4)-Has-violated-this-chapter,-any-rule-of-the-board-promulgated-un---10-der-this-act,-an-order-of-the-board-or-any-federal-regulation-relating-to-1-1-controlled-substances;-provided,-however,-that-no-restriction,-revoca---12-tion-or-suspension-procedure-be-initiated-under-this-paragraph-without-13-the-board-first-giving-notice-of-the-procedure-to-the-state-licensing-14-board-with-authority-over-the-registrant's-professional-license.-15-(b)-The-notice-required-in-subsection-(a)(4)-of-this-section-shall-be-16-given-immediately-in-the-event-action-is-taken-without-an-order-to-show-cause-17-as-allowed-under-section-37---2719(b),-Idaho-Code.-In-all-other-cases,-such-18-notice-shall-be-given-as-early-as-reasonably-practicable-without-risking-19-compromise-of-the-board's-investigation-but-no-later-than-the-earlier-of:-20-(1)-Issuance-of-an-order-to-show-cause-under-section-37---2719(a),-Idaho-21-Code;-or-22-(2)-Setting-of-a-hearing-for-approval-of-a-resolution-of-the-matter-23-through-informal-proceedings.-24-(c)-Restriction,-revocation-or-suspension-procedures-arising-solely-25-from-"practice---related-issues"-shall-be-referred-by-the-board-to-such-regis---26-trant's-state-licensing-board.-27-(1)-Upon-such-referral,-the-registrant's-state-licensing-board-shall-28-commence-such-investigation-of-the-referred-matter-as-it-deems-neces---29-sary-and-shall-take-action-upon-the-registrant's-license-or-shall-inform-30-the-board-of-pharmacy,-in-writing,-that-it-has-investigated-the-referred-31-matter-and-has-concluded-that-no-action-is-necessary.-32-(2)-For-purposes-of-this-section,-the-term-"practice---related-issues"-33-refers-to-issues-involving-questions-regarding-the-professional-con---34-duct-of-the-registrant-within-the-scope-of-the-registrant's-profession.-35-(d)-The-board-may-limit-the-revocation-or-suspension-of-a-registration-36-to-the-particular-controlled-substance-with-respect-to-which-grounds-for-re---37-vocation-or-suspension-exist.-38-(e)-If-the-board-restricts,-suspends-or-revokes-a-registration,-all-39-pertinent-controlled-substances-owned-or-possessed-by-the-registrant-at-the-40-time-of-the-restriction-or-suspension-or-the-effective-date-of-the-revocation-41-order-may-shall-be-placed-under-seal.-No-disposition-may-be-made-of-sub---42-stances-under-seal-until-the-time-for-taking-an-appeal-has-elapsed-or-until-43-all-appeals-have-been-concluded-unless-a-court,-upon-application-therefor,-44-orders-the-sale-of-perishable-substances-and-the-deposit-of-the-proceeds-of-45-the-sale-with-the-court.-Upon-a-revocation-order-becoming-final,-all-con---46-trolled-substances-may-be-forfeited-to-the-state-for-transfer-to-a-reverse-47-distributor-.-48-(f)-The-board-shall-promptly-notify-the-bureau-and-the-state-licensing-49-board-with-authority-over-the-registrant's-professional-license-of-all-or---50--25-ders-restricting,-suspending-or-revoking-registration-and-all-forfeitures-1-of-controlled-substances.-2-(g)-In-the-event-the-drug-enforcement-administration-or-a-state-li---3-censing-board-with-authority-over-a-registrant's-professional-license-or-4-registration-takes-an-action-against-the-registrant-in-any-fashion-which-5-suspends,-restricts,-limits-or-affects-the-registrant's-ability-to-manufac---6-ture,-distribute,-prescribe,-administer,-dispense,-or-conduct-research-with-7-any-controlled-substance,-the-professional-licensing-board-shall-promptly-8-notify-the-board-of-pharmacy-of-the-action.-9-(1)-Upon-such-action,-the-board-of-pharmacy-shall-be-authorized-to-issue-10-its-order-suspending,-restricting,-limiting-or-otherwise-affecting-the-1-1-registrant's-controlled-substance-registration-in-the-same-fashion-as-12-the-professional-licensing-board-action.-13-(2)-The-board-of-pharmacy-order-may-be-issued-without-further-hearing-or-14-proceeding,-but-shall-be-subject-to-the-effect-of-any-reversal-or-modi---15-fication-of-the-professional-licensing-board-action-by-reason-of-any-ap---16-peal-or-rehearing.-17-SECTION-9.-That-Section-37---2719,-Idaho-Code,-be,-and-the-same-is-hereby-18-amended-to-read-as-follows:-19-37---2719.-ORDER-TO-SHOW-CAUSE.-(a)-Except-as-set-forth-in-section-20-37---2718(g),-Idaho-Code,-before-denying,-restricting,-suspending-or-revoking-21-a-registration,-or-refusing-a-renewal-of-registration,-the-board-shall-serve-22-upon-the-applicant-or-registrant-an-order-to-show-cause-why-the-registration-23-should-not-be-restricted,-denied,-revoked,-or-suspended,-or-why-the-renewal-24-should-not-be-refused.-The-order-to-show-cause-shall-contain-a-statement-25-of-the-basis-therefor-for-discipline-and-shall-call-upon-the-applicant-or-26-registrant-to-appear-before-the-board-at-a-time-and-place-not-less-than-thirty-27-(30)-days-after-the-date-of-service-of-the-order,-but-in-the-case-of-a-an-28-anticipated-denial-or-of-renewal-of-registration-the-show-cause-order-shall-29-be-served-not-later-than-thirty-(30)-days-before-the-expiration-of-the-reg---30-istration.-These-proceedings-shall-be-conducted-in-accordance-with-chapter-31-52,-title-67,-Idaho-Code,-without-regard-to-any-criminal-prosecution-or-other-32-proceeding.-Proceedings-to-refuse-renewal-of-registration-shall-not-abate-33-the-existing-registration-which-shall-remain-in-effect-pending-the-outcome-34-of-the-administrative-hearing.-35-(b)-The-board-may-suspend,-without-an-order-to-show-cause,-any-regis---36-tration-simultaneously-with-the-institution-of-proceedings-under-section-37-37---2718,-Idaho-Code,-or-where-renewal-of-registration-is-refused,-if-it-finds-38-that-there-is-an-imminent-danger-to-the-public-health-or-safety-which-war---39-rants-this-action.-The-suspension-shall-continue-in-effect-until-the-conclu---40-sion-of-the-proceedings,-including-judicial-review-thereof,-unless-sooner-41-withdrawn-by-the-board-or-dissolved-by-a-court-of-competent-jurisdiction.-42-(c)-In-conjunction-with-a-proceeding-for-denying,-restricting,-sus---43-pending-or-revoking-a-registration,-or-refusing-a-renewal-of-registration,-44-and-upon-a-finding-of-grounds-for-such-denial,-restriction,-suspension,-45-revocation-or-refusal-to-renew,-the-board-may-also-impose-an-a-reasonable-ad---46-ministrative-fine-not-to-exceed-two-thousand-dollars-($2,000)-per-occurrence-47-and-additionally-may-include-forfeiture-of-illicit-profits-and-the-costs-of-48--26-prosecution-and-administrative-costs-of-bringing-the-action-including,-but-1-not-limited-to,-attorney's-fees-and-costs-and-costs-of-hearing-transcripts.-2-SECTION-10.-That-Section-37---2720,-Idaho-Code,-be,-and-the-same-is-hereby-3-amended-to-read-as-follows:-4-37---2720.-RECORDS-----DRUG-STORAGE-----INVENTORY.-Persons-registered-un---5-der-this-chapter-shall-keep-records,-store-controlled-substances-and-main---6-tain-inventories-in-conformance-with-the-recordkeeping,-storage-and-inven---7-tory-requirements-of-state-and-federal-law-and-with-any-additional-rules-the-8-board-issues-.-9-SECTION-11.-That-Section-37---2722,-Idaho-Code,-be,-and-the-same-is-hereby-10-amended-to-read-as-follows:-1-1-37---2722.-ISSUING,-DISTRIBUTING,-AND-DISPENSING-OF-CONTROLLED-SUB---12-STANCES.-No-person-shall-issue-or-dispense-a-prescription-drug-order-for-a-13-controlled-substance-unless-it-is-in-compliance-with-applicable-state-and-14-federal-law-and-rules-of-the-board-.-15-(a)-Controlled-substances-included-in-schedule-I-shall-be-distributed-16-only-by-a-registrant-to-another-registrant-pursuant-to-the-federal-drug-en---17-forcement-administration-(DEA)-order-form-222.-18-(b)-Controlled-substances-included-in-schedule-II-shall:-19-(1)-Be-distributed-only-by-a-registrant-to-another-registrant-pursuant-20-to-DEA-order-form-222.-21-(2)-Be-dispensed-only-pursuant-to-a-valid-prescription-drug-order,-ex---22-cept-when-dispensed-directly-by-a-prescriber.-23-(3)-Not-be-refilled.-24-(4)-Include-a-quantity-that-is-both-spelled-out-in-English-and-written-25-in-numerical-form,-when-a-written-prescription-drug-order-is-required.-26-(c)-Controlled-substances-included-in-schedule-III-or-IV-shall:-27-(1)-Be-dispensed-only-pursuant-to-a-valid-prescription-drug-order,-ex---28-cept-when-dispensed-directly-by-a-prescriber.-29-(2)-Not-be-filled-or-refilled-more-than-six-(6)-months-after-the-date-30-thereof-or-be-refilled-more-than-five-(5)-times,-unless-renewed-by-the-31-practitioner.-32-(d)-Controlled-substances-included-in-schedule-V-shall-not-be-dis---33-tributed-or-dispensed-other-than-for-a-medical-purpose.-34-(e)-A-pharmacist-may-dispense-a-controlled-substance-pursuant-to-a-35-valid-prescription-drug-order-of-an-individual-licensed-in-a-jurisdiction-36-other-than-the-state-of-Idaho-as-long-as-the-individual-is-acting-within-the-37-jurisdiction,-scope-and-authority-of-his-license.-38-(f)-Prior-to-issuing-to-a-patient-a-prescription-for-outpatient-use-39-for-an-opioid-analgesic-or-benzodiazepine-listed-in-schedule-II,-III,-or-40-IV,-the-prescriber-or-the-prescriber's-delegate-shall-review-the-patient's-41-prescription-drug-history-for-the-preceding-twelve-(12)-months-from-the-pre---42-scription-drug-monitoring-program-and-evaluate-the-data-for-indicators-of-43-prescription-drug-diversion-or-misuse.-This-review-is-not-required:-44-(1)-For-patients:-45-(i)-i.-Receiving-treatment-in-an-inpatient-setting;-46-(ii)-ii.-At-the-scene-of-an-emergency-or-in-an-ambulance;-47--27-(iii)-iii.-In-hospice-care;-or-1-(iv)-iv.-In-a-skilled-nursing-home-care-facility;-or-2-(2)-For-a-prescription-in-a-quantity-intended-to-last-no-more-than-three-3-(3)-days.-4-(g)-Subsection-(f)-of-this-section-shall-be-effective-on-and-after-Octo---5-ber-1,-2020,-and-shall-apply-only-to-individuals-required-by-this-chapter-to-6-register-fortheprescriptiondrugmonitoringprogram.-7-SECTION-12.-That-Section-37---2726,-Idaho-Code,-be,-and-the-same-is-hereby-8-amended-to-read-as-follows:-9-37---2726.-FILING-PRESCRIPTIONS-----DATABASE.-(1)-All-controlled-sub---10-stances-and-opioid-antagonists-as-defined-in-section-54---1704,-Idaho-Code,-1-1-dispensed-for-humans-shall-be-filed-with-the-division-electronically-in-a-12-format-established-by-the-division.-The-division-may-require-the-filing-of-13-other-prescriptions-by-law-or-rule.-The-division-shall-establish-the-in---14-formation-to-be-submitted-pursuant-to-the-purposes-of-this-section-and-the-15-purposes-set-forth-in-section-37---2730A,-Idaho-Code.-16-(2)-The-division-shall-create,-operate-and-maintain-a-controlled-17-substances-prescriptions-database-containing-the-information-submitted-18-pursuant-to-subsection-(1)-of-this-section-to-be-used-for-the-purposes-19-and-subject-to-the-terms,-conditions-and-immunities-described-in-section-20-37---2730A,-Idaho-Code.-The-division-shall-retain-the-information-submitted-21-pursuant-to-subsection-(1)-of-this-section-for-a-period-of-five-(5)-years-from-22-the-date-the-controlled-substance-was-dispensed.-The-database-information-23-must-may-be-made-available-only-to-the-following:-24-(a)-Authorized-individuals-employed-by-the-division,-Idaho's-boards,-25-or-other-states'-licensing-entities-charged-with-the-licensing-and-dis---26-cipline-of-practitioners;-27-(b)-Peace-officers-and-investigators-employed-by-federal,-state-and-lo---28-cal+It+also+includes+technical+cleanup+revisions+to+simplify+statutory+language,+eliminate+redundancy+,+and+ensure+the+Act+remains+accurate,+legally+consistent,+and+responsive+to+evolving+public+health+andlawenforcement+priorities.+These+updates+provide+greater+clarity+and+utility+for+law+enforcement,+prosecutors,+healthcare+providers,+and+regulatoryagencies-engaged-as-a-specified-duty-of-their-em---29-ployment-in-enforcing-law-regulating-controlled-substances;-30-(c)-Authorized-individuals-under-the-direction-of-the-department-of-31-health-and-welfare-for-the-purpose-of-monitoring-and-enforcing-that-32-department's-responsibilities-under-the-public-health,-medicare-and-33-medicaid-laws;-34-(d)-A-practitioner,-licensed-in-Idaho-or-another-state,-having-author---35-ity-to-prescribe-controlled-substances,-or-a-delegate-under-the-prac---36-titioner's-supervision,-to-the-extent-the-information-relates-specifi---37-cally-to-a-current-patient-of-the-practitioner-to-whom-the-practitioner-38-is-prescribing-or-considering-prescribing-any-controlled-substance;-39-(e)-A-pharmacist,-licensed-in-Idaho-or-another-state,-having-author---40-ity-to-dispense-controlled-substances,-or-a-delegate-under-the-pharma---41-cist's-supervision,-to-the-extent-the-information-relates-specifically-42-to-a-current-patient-to-whom-that-pharmacist-is-dispensing-or-consid---43-ering-dispensing-any-controlled-substance,-or-providing-pharmaceutical-44-care-as-defined-in-the-Idaho-pharmacy-act;-45-(f)-An-individual-who-is-the-recipient-of-a-dispensed-controlled-sub---46-stance-entered-into-the-database-may-access-records-that-pertain-to-that-47-individual,-upon-the-production-of-positive-identification,-or-that-in---48-dividual's-designee-upon-production-of-a-notarized-release-of-informa---49--28-tion-by-that-individual-that-is-notarized-or-otherwise-certified-pur---1-suant-to-section-9---1406,-Idaho-Code-;-2-(g)-Upon-a+responsible+for+thelawful-order-issued-by-the-presiding-judge-in-a-court-of-com---3-petent-jurisdiction-for-the-release-of-prescription-monitoring-program-4-records-of-a-named-individual;-5-(h)-Prosecuting-attorneys,-deputy-prosecuting-attorneys-,-and-special-6-prosecutors-of-a-county-or-city-employed-by-federal,-state,-county,-or-7-local-agencies-and-special-assistant-attorneys-general-from-the-office-8-of-the-attorney-general-engaged-in-enforcing-law-regulating-controlled-9-substances;-and-10-(i)-A-medical-examiner-or-coroner-who-is-an-officer-of-or-employed-by-a-1-1-state-or-local-government,-for-determining-a-cause-of-death-or-for-per---12-forming-other-duties-authorized-by-law.-13-(3)-The-division-shall-require-pharmacists-and-prescribers,-except-14-veterinarians,-to-register-with-the-division-to-obtain-online-access-to-the-15+handling,+prescribing,+and+enforcement+ofcontrolledsubstances-prescriptions-database.-16-(4)-(3)-The-division-must-maintain-records-on-the-information-disclosed-17-from-the-database,-including:-18-(a)-The-identification-of-each-individual-who-requests+in+the+state.+FISCAL+NOTE+This+legislation+is+expected+to+have+a+neutral+fiscal+impact+across+all+fund+sources.+No+additional+costsor-receives-in---19-formation-from-the-database-and-who-that-individual-represents;-20-(b)-The-information-provided-to-each-such-individual;-and-21-(c)-The-date-and-time-the-information-is-requested-or-provided.-22-(5)-(4)-The-division-shall-ensure-that-only-authorized-individuals-have-23-access-to-the-database.-24-(6)-(5)(a)-Any-person-who-knowingly-misrepresents-to-the-division-that-25-he-is-a-person-entitled-under-subsection-(2)-of-this-section-to-receive-26-information-from-the-controlled-substances-prescriptions-database-un---27-der-the-conditions-therein-provided,-and-who-receives-information-from-28-the-controlled-substances-prescriptions-database-resulting-from-that-29-misrepresentation,-A-person-is-guilty-of-a-misdemeanor-if-such-person:-30-(i)-Knowingly-misrepresents-to-the-division-that-he-is-a-person-31-entitled-to-receive-information-from-the-controlled-substances-32-prescriptions-database-pursuant-to-subsection-(2)-of-this-section-33-and-receives-information-from-the-controlled-substances-prescrip---34-tions-database-as-a-result-of-such-misrepresentation;-35-(ii)-Knowingly-discloses-information-obtained-from-the-con---36-trolled-substances-prescriptions-database-that-identifies-an-in---37-dividual-patient-to-a-person-not-authorized-to-receive-or-use-such-38-information-under-any+revenue+changes+are+anticipated+for+thestate+General+Fund,+dedicated+funds,orfederal-law,-rule,-or-regulation,-39-without-the-lawful-order-of+funds.+Contact:+Representative+Marco+Adam+Erickson+Senator+Brandon+Shippy+(208)+322-1000+DISCLAIMER:+This+statement+of+purpose+and+fiscal+note+ar+ea-court-of-competent-jurisdiction,-or-40-without-written-authorization.-The-provisions-of+mer+e+attachment+tothis-subpara---41-graph-shall-not-apply-to-disclosure-of-individual-patient-infor---42-mation-by-the-patient-himself-or-disclosure-of-individual-patient-43-information+bill+and+pr+epar+edbya-federal,-state,-or-local-prosecuting-attorney,-44-a-deputy-prosecuting-attorney-or-special-prosecutor,-or-a-special-45-assistant-attorney-general-from-the-office-of-the-attorney-general-46-in-the-course-of-a-criminal-proceeding,-whether-preconviction-or-47-post---conviction;-or-48-(iii)-Intentionally-shares-or-recklessly-fails-to-safeguard-a-49-division---issued-user-account,-login-name,-or-password,-result---50--29-ing-in-another-person-obtaining-information-from-the-controlled-1-substances-prescriptions-database-when-such-other-person+pr+oponent+of+the+bill.+Itis-not-2-authorized-to-receive-or+neither+intended+as+an+expr+ession+of+legislative+intent+nor+intended+for+anyuse-such-information-under-the-provisions-3-of-any-state-or-federal-law,-rule,-or-regulation.-4-(b)-Any-person-who-violates-the-provisions-of-paragraph-(a)-of-this-sub---5-section-shall-be-guilty-of-a-misdemeanor,-punishable-by-imprisonment-in-6-a-county-jail-not-to-exceed-six-(6)-months,-or-by-a-fine-not-to-exceed-7-two-thousand-dollars-($2,000),-or-both.-The-foregoing-criminal-penalty-8-is-in-addition-to,-and-not-in-lieu-of,-any-other-civil-or-administrative-9-penalty-or-sanction-authorized-by-law.-10-(7)-Any-person-in-possession,-whether-lawfully-or-unlawfully,-of-infor---1-1-mation-from-the-controlled-substances-prescriptions-database-that-identi---12-fies-an-individual-patient-and-who-knowingly-discloses-such-information-to-a-13-person-not-authorized-to-receive-or-use-such-information-under-any-state-or-14-federal-law-or-rule-or-regulation,-or-the-lawful-order-of-a-court-of-competent-15-jurisdiction,-or-without-written-authorization-of-the-individual-patient-16-shall-be-guilty-of-a-misdemeanor,-punishable-by-imprisonment-in-a-county-jail-17-not-to-exceed-six-(6)-months,-or-by-a-fine-not-to-exceed-two-thousand-dollars-18-($2,000),-or-both.-The-foregoing-criminal-penalty-is-in-addition-to,-and-not-19-in-lieu-of,-any-other-civil-or-administrative-penalty-or-sanction-authorized-20-by-law.-The-provisions-of-this-subsection-shall-not-apply-to-disclosure-of-21-individual-patient-information-by-the-patient-himself.-The-provisions-of-22-this-subsection-shall-not-apply-to-disclosure-of-information-by-a-prosecut---23-ing-attorney,-deputy-prosecuting-attorney-or-special-prosecutor-of-a-county-24-or-city-or-by-a-special-assistant-attorney-general-from-the-office-of-the-at---25-torney-general-in-the-course-of-a-criminal-proceeding,-whether-preconviction-26-or-postconviction.-27-(8)-Any-person-with-access-to-the-division's-online-prescription-mon---28-itoring-program-pursuant-to-a-division---issued-user-account,-login-name-and-29-password-who-intentionally-shares-or-recklessly-fails-to-safeguard-his-user-30-account,-login-name-and-password,-resulting-in-another-person-not-authorized-31-to-receive-or-use-such-information-under-the-provisions-of-any-state-or-fed---32-eral-law,-rule-or-regulation-obtaining-information-from-the-controlled-sub---33-stances-prescriptions-database,-shall-be-guilty-of-a-misdemeanor,-punish---34-able-by-imprisonment-in-a-county-jail-not-to-exceed-six-(6)-months-or-by-a-fine-35-not-to-exceed-two-thousand-dollars-($2,000),-or-both.-The-foregoing-criminal-36-penalty-is-in-addition-to,-and-not-in-lieu-of,-any-other-civil-or-administra---37-tive-penalty-or-sanction-authorized-by-law.-38-(9)-(6)-The-division-may,-at-its-discretion,-block-access-to-certain-39-controlled-substances-prescriptions-database-data-if-the-division-has-rea---40-son-to-believe-that-access-to-the-data-is-or-may-be-used-illegally.-41-(10)-(7)-All-costs-associated-with-recording-and-submitting-data-as-re---42-quired-in-this-section-are-assumed-by-the-dispensing-practitioner-recording-43-and-submitting-the-data.-44-(11)-(8)-For-purposes-of-this-section,-"delegate"-means-a-nurse,-medi---45-cal-or-office-assistant,-current-student-of-a-health-profession-if-the-health-46-care-staff,-current-health-profession-student-of-a-licensed-practitioner-or-47-registered-graduate-of-such-profession-who-may-access-the-database,-or-a-reg---48-istered-pharmacy-technician-who-is-designated-by-a-supervising-practitioner-49--30-or-pharmacist-to-access-the-database-according-to-the-provisions-of-this-sec---1-tion-and-who-must-register-with-the-division-for-such-access.-2-SECTION-13.-That-Section-37---2731,-Idaho-Code,-be,-and-the-same-is-hereby-3-amended-to-read-as-follows:-4-37---2731.-INFORMATION-REQUIRED-ON-LABEL.-A-practitioner-with-statutory-5-authority-to-dispense-a-controlled-substance-shall-affix-to-the-package-a-la---6-bel-pursuant-to-board-rule-Idaho-law-.-7-SECTION-14.-An-emergency-existing-therefor,-which-emergency-is-hereby-8-declared-to-exist,-this-act-shall-be-in-full-force-and-effect-on-and-after-9-July-1,-2026.-10+outside+of+the+legislative+pr+ocess,+including+judicial+r+eview+(Joint+Rule+18).+Statement+of+Purpose+/+Fiscal+Note+Bill+SOP/FN+INTRODUCED:+02/25/2026,+10:21+AM
Diffs are computed deterministically from extracted bill text and show additions, deletions, and section moves. Scanned-PDF text extracted via OCR is flagged where confidence is low; see methodology.